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Abstract
  Adrenocortical carcinoma (ACC) is a rare yet highly aggressive form of 
cancer with limited treatment options and poor prognosis.  Insulin-like growth 
factor 2 (IGF2) is one of the most highly expressed genes in sporadic ACC, and 
is an adrenal mitogen.  In addition, a microRNA (miRNA), miR-483-3p, is located 
in an intronic region of IGF2, suggesting co-expression of IGF2 and miR-483-3p 
in ACC.  miRNAs are small, endogenous, non-protein coding RNAs that are an 
important means of post-transcriptional gene regulation, and have been 
implicated in numerous physiologic and disease processes. This thesis describes 
the correlation between IGF2 and miR-483-3p in primary human ACC samples, 
providing rationale for the development of molecular tools designed to aid in the  
study of the role of IGF2  and miR-483-3p in ACC.  Additionally, we describe the 
results of genetically deleting Dicer, a key miRNA processing enzyme, in the 
developing adrenal cortex.  Adrenal Dicer knockout (KO) mice did not survive 
beyond 24-48 hours post-parturition, and were characterized by rapid failure of 
the adrenal cortex during late gestation at embryonic day 18.5 (E18.5).  
Specifically, Dicer KO adrenal cortical cells underwent apoptosis and were 
completely depleted by E18.5.  The adrenal medulla, however, remained in 
E18.5 Dicer KO adrenals, suggesting that initial adrenal cortex formation was 
unperturbed by Dicer inactivation.  To further characterize Dicer KO embryonic 
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adrenals, we subjected purified RNA isolated from control and KO adrenals at 
both E15.5 and E16.5 to mRNA and miRNA microarray analyses.  Intriguingly, 
Dicer KO adrenals demonstrated significant up-regulation of transcripts 
belonging to the genes Nr6a1 and Acvr1c, whose functions in adrenocortical 
development and physiology are currently poorly understood.  Finally, several 
down-regulated miRNAs in Dicer KO adrenals were consistently predicted to 
target mRNA transcripts from these genes.  The increased expression of Nr6a1 
and Acvr1c gene transcripts in Dicer KO adrenals may suggest a role for miRNA 





 Four hundred and fifty years ago, an Italian anatomist by the name of 
Bartolomeo Eustachi (Eustachius) described the presence of the suprarenal 
bodies, ‘Glandulae renis incumbentes’, in his work Opuscula Anatomica.  He did 
not, however, offer any explanation on their function.  At the time, Eustachius 
stated that no one had previously described the glands now known as the 
adrenals in any medical work, although there is some debate as to whether the 
early Roman physician Galen may have described them as early as the second 
century AD [1].  While Eustachius remains a well known establishment of the 
medical community in the twenty-first century due in part to the tube in the inner 
ear that bears his name, he is often overlooked concerning the history of the 
adrenal gland.  It was not until nearly 300 years later, in 1855, that the adrenal 
glands finally came to the forefront of the burgeoning field of endocrinology.  It 
was in this year that a renowned English physician, Thomas Addison, published 
his book, On the Constitutional and Local Effects of Disease of the Suprarenal 
Capsules, in which he described 10 cases of patients suffering with what would 
eventually come to be identified as Addison’s Disease [2].  With the renewed 
interest in the ‘suprarenal capsules’ and their association with a profile of disease 
symptoms, the floodgates of research into the adrenal glands were opened.  The 
1
following year, Brown-Séquard proved in animal experiments that the adrenal 
glands were essential for life.  Then, towards the beginning of the twentieth 
century, Sir William Osler demonstrated the temporary effective treatment of 
Addison’s Disease by the administration of a crude, oral extract prepared from 
adrenal glands, proving that their still unidentified secretions were important for 
health.  Through the early twentieth century into the 1930s, further experiments 
in animal models supported Osler’s initial observation, and the involvement of the 
pituitary gland in what is now known as the hypothalamic-pituitary-adrenal (HPA) 
axis was first described.  As advances in biochemistry were made through World 
War II and beyond, the steroid hormones of the adrenal cortex were isolated, and 
their structures determined and synthesized.  In 1942 adrenocorticotropic 
hormone (ACTH), the pituitary hormone responsible for stimulating steroid 
production in the adrenal cortex, was isolated by Li and Sayers; shortly 
afterwards the anti-inflammatory effects of cortisol were discovered by Hench in 
1948.  By the end of the 1950s, aldosterone had been isolated and 
characterized.  Jerome W. Conn, a University of Michigan Medical School 
alumnus and endocrinologist, was the first to describe the disease of primary 
aldosteronism which now bears his name [3].
 In the 157 years since Addison rekindled scientific interest in the adrenal 
glands, the biochemical, anatomical, and physiologic aspects of the glands and 
their functions have been elucidated in great detail.  Their role in maintaining 
electrolyte homeostasis, mediating physiologic responses to stress and external 
stimuli, and the regulatory feedback pathways involved in adrenal function are 
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now standard fare for any first year medical student around the world.  The 
advent of the ‘molecular age‘ of research as the twenty-first century gets 
underway opens the door for new directions of adrenal research.  The molecular 
ontogeny of the adrenal gland is one of these avenues.  The molecular and 
cellular signaling processes necessary for adrenal formation are still poorly 
defined, and the molecular mechanisms of maintenance and homeostasis of the 
adrenal cortex are still in the relatively early stages of discovery.  The molecular 
and genetic factors that keep the balance between adrenal physiology, 
pathophysiology, and neoplasia, and the events that upset this balance still 
remain elusive as well; they are also a subject of great interest for the current 
and next generation of physicians and researchers.  The information gathered 
from genetic and molecular studies of the adrenal gland will provide insights and 
answers to questions regarding the factors that contribute to adrenal 
development, function, and disease.  From the simple yet foundational 
advancements made in adrenal biology from the nineteenth century onwards, the 
knowledge gleaned from present day adrenal research will serve to propel our 
understanding of adrenal pathology well into the twenty-first century and beyond, 
ushering in a new era of treatments for adrenal and endocrine related disease.  
Adrenal Structure and Function
 The adrenal glands are bilateral endocrine organs situated superior to the 
kidneys.  In mice, they are grossly spherical or ellipsoid in shape, with a fairly 
uniform radial organization and appearance when viewed in cross section.  In 
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humans, the glands appear grossly pyramidal in shape, and often have 
invaginations that make them irregular in cross section, with the internal 
organization seemingly flattened or folded.  The human adrenal is divided into 
the head, body, and tail, from the inferomedial to superior aspects, highlighting its  
irregular shape in comparison with the mouse.  The adrenals in humans and 
mice are surrounded by a thin capsule that surrounds the cortical tissue.  Current 
research suggests that this capsule plays an important function in the 
maintenance of the adrenal cortex [4].  The adrenal gland is divided into two 
grossly defined zones, the outer cortex and the inner medulla (Figure 1.1).  The 
cortex is further subdivided into three concentric functional zones, which are 
defined by their biochemical and steroid producing profiles.  Beginning from the 
outermost zone, these are the zona glomerulosa (zG), zona fasiculata (zF), and 
zona reticularis (zR).  In rodents and other animals, the functional distinction 
between the zF and zR is often less distinct when compared with the human 
adrenal [5].  Vascular supply is provided via branches from the aorta, renal, and 
inferior phrenic arteries, which form a capsular plexus that flows into a capillary 
network in the outer margin of the zG.  Sinusoids in the zF, zR, and medulla 
eventually drain into the adrenal central vein, which then flows back into the 
venous return system.  Innervation of the adrenal gland is well established in 
regards to the direct regulation of catecholamine synthesis by the adrenal 
medulla.  Sympathetic preganglionic and cholinergic fibers derived from the 
splanchnic nerves synapse directly on the cells of the medulla.  Recent studies, 
however, have demonstrated that the cortical cells may also receive direct 
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neuronal synapses [6,7].  In addition, evidence exists supporting the notion that 
the cortex may also contain sensory innervation, with afferent nerve fibers 
providing feedback to the central nervous system in response to adrenal specific 
stimuli.  Finally, the presence of numerous neuropeptides and transmitters in the 
adrenal cortex and medulla also suggest a rich network of innervation in the 
gland [8-10].  
 As stated previously, the adrenal gland is divided grossly into the medulla 
and cortex.  The adrenal medulla is comprised of chromaffin cells, so named by 
the Prague histologist Alfred Kohn at the turn of the nineteenth century because 
of their apparent affinity to chromium salts that resulted in a yellow-brown 
staining [11].  Indeed, it had been observed earlier in that same century by the 
French physician, Edmé Félix Alfred Vulpian, that an unknown substance in the 
adrenal medulla reacted with perchloride of iron to produce an emerald green 
stain not seen elsewhere in the human body [3].  It is now known that the 
unknown substances that caused the colored stains in Kohn and Vulpian’s 
experiments were catecholamines synthesized by the adrenal medullary cells.  
This discovery was made shortly after Kohn coined the term “chromaffin”, when 
adrenaline (epinephrin) was isolated and synthesized.  Epinephrine, 
norepinephrine, and dopamine are the endogenous secretions of the adrenal 
medulla, and belong to a class of compounds known as catecholamines.  They 
are characterized by an amine group containing a 3,4-dihydroxyphenyl (catechol) 
nucleus, and are synthesized from the amino acid tyrosine involving a series of 
biochemical steps mediated by enzymes produced by the medullary cells.  The 
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majority of medullary cells synthesize, store, and secrete epinephrine.  A small 
minority lack the enzyme phenylethanolamine N-methyl transferase (PMNT), 
which is necessary to catalyze the final step from norepinephrine to epinephrine; 
these cells can only secrete norepinephrine.  Interestingly,  PMNT expression is 
induced by glucocorticoids, raising the possibility of cortical-medullary signaling 
in the maintenance of epinephrine secreting medullary cells [12].  The biological 
functions of the catecholamines are mediated through adrenergic receptors 
found on the cell membranes of target cells.  This class of receptors is broadly 
divided between α and β receptors, with each class further subdivided into 
subtypes α1, α2 and β1, β2.  Catecholamines produces a variety of physiologic 
effects, although their effects on blood pressure and glucose metabolism are 
among the most widely known.  Among the hemodynamic effects of 
catecholamines are increased myocardial contraction (β1), vasoconstriction (α), 
and vasodilation (β2).  The metabolic effects of catecholamine stimulation include 
a hyperglycemic effect that is facilitated in part by increased hepatic glucose 
production [10].  These effects together, are in part responsible for the so-called 
“fight or flight” stress response that the medullary catecholamines are known to 
facilitate.
 Despite the importance of the adrenal medulla in synthesizing and storing 
catecholamines, the adrenal cortex plays an equal, if not more critical role, in 
maintaining physiologic homeostasis by secreting functionally distinct hormones 
from a population of cells thought to have common origins.  The adrenal cortex 
produces three main classes of steroid hormones: mineralocorticoids, 
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glucocorticoids, and sex steroids.  The separately controlled secretion of these 
steroids is critical, and is accomplished in part by cellular differentiation and 
zonation of the adrenal cortex (Figure 1.2).  Mineralocorticoids (primarily 
aldosterone) are produced by the zG, primarily under the influence of the renin-
angiotensin system.  Renin is produced by the kidney in response to decreased 
perfusion, decreased sodium balance, and sympathetic stimulation.  Renin acts 
upon its zymogen substrate, angiotensinogen, which is produced by the liver, to 
generate angiotensin I.  Angiotensin converting enzyme converts angiotensin I 
into active angiotensin II, which acts on the adrenal zG to stimulate aldosterone 
secretion.  Aldosterone exerts its primary effects on the distal convoluted tubule 
of the kidney nephron to promote the resorption of sodium from the urine.  In 
doing so, aldosterone facilitates the maintenance of fluid and electrolyte balance 
in the organism.  The secretion of glucocorticoids is the task of the zF, and is 
controlled primarily by the HPA axis through the effects of ACTH, a peptide 
hormone secreted by the anterior pituitary.  ACTH is a product of a larger 
precursor peptide, pro-opiomelanocortin (POMC) that is secreted by the anterior 
pituitary.  POMC undergoes a series of endoproteolytic cleavage steps to 
produce ACTH, in addition to several other melanocortin-related peptides.  While 
ACTH secretion is episodic and correlates with the circadian rhythm of the 
organism, stress, both emotional and physical, is also a significant stimulator of 
ACTH release into the bloodstream.  The physiologic effects of glucocorticoids 
are too numerous and substantial to describe fully in this work, but briefly, 
glucocorticoids affect metabolic functions by promoting protein catabolism, 
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hepatic gluconeogenesis, and inhibiting glucose uptake and usage in peripheral 
tissues.  Additionally, prolonged exposure to glucocorticoids leads to a re-
distribution of fat mass, resulting in characteristic “moon facies”, truncal obesity, 
and other features of Cushing’s syndrome.  Glucocorticoids also negatively 
regulate growth and wound healing, and repress the inflammatory response of 
the immune system, making them highly effective anti-inflammatory drugs.  
Finally, the last class of steroid hormones produced by the adrenal cortex are 
androgens, with dehydroepiandrosterone sulfate (DHEA-S) being one of the 
primary adrenal androgens.  Like the secretion of glucocorticoids from the zF, 
androgen secretion from the zR is stimulated primarily by ACTH.  While the 
testes produce more androgens than the zR, adrenal androgens are converted to 
more potent androgens in the periphery.  In rodents and humans, both the zF 
and zR are capable of synthesizing androgens, although the sulfation of steroids 
appears to be specific to the zR [9,10].      
 This complex organization of the adrenal gland is a result of its equally 
complex developmental program.  In the next section, the developmental steps of 
the adrenal gland will be outlined, with an emphasis on the underlying molecular 
mechanisms and the relatively new field of adrenal stem cells and maintenance.   
Adrenal Development
 Adrenal development is characterized by a series of discrete histological 
events under the control of specific molecular signaling mechanisms (Figure 1.3). 
The adrenal cortex originates from a cellular condensation of the coelomic 
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epithelium known as the urogenital ridge, which additionally gives rise to both the 
kidney and gonads.  In the mouse, the adrenogonadal primodrium (AGP), which 
eventually gives rise to both the adrenal cortex and the gonads, becomes 
apparent at approximately embryonic day 9.5 (E9.5).  An analogous initial phase 
also occurs in the human fetus at around the 4th week of gestation.  The orphan 
nuclear receptor, steroidogenic factor 1 (Sf1) is a useful molecular marker to 
distinguish this group of cells.  After this point, the adrenal and gonadal lineages 
become distinct.  By E12.5, neural crest cells infiltrate the developing adrenal 
primordium, eventually becoming the adrenal medulla.  The same occurs in the 
human at approximately the 9th week of gestation.  In both humans and mice, 
the developing adrenal cortex is initially comprised of what is known as the fetal 
adrenal cortex.  This fetal cortex is eventually replaced by the definitive adult 
cortex, and regresses in humans during the weeks following birth.  In mice, the 
fetal cortex (sometimes referred to as the X-zone) enlarges until 3 weeks of age, 
then in males degenerates following puberty whereas in female mice the X-zone 
persists until the first pregnancy [13-16].
 The expression of Sf1 is necessary for adrenal and gonadal development, 
as Sf1 deficient mice die shortly after birth and lack both adrenals and gonads 
[17].  Sf1 expression is first detectable in the mouse at E9.5, when it initiates the 
transcriptional signaling cascades that lead to adrenocortical development, 
differentiation, and maintenance.  However there are numerous other regulatory 
factors and signaling pathways that have been implicated in adrenal 
development and maintenance.  Wt1, or Wilms Tumor 1, is also required for 
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adrenal formation, and Wt1 null mice demonstrate an adrenal aplasia phenotype 
[18].  Additionally, the CBP/p300-interacting transactivator with ED-rich tail 2 
(Cited2) and the pre-B cell leukemia homeobox 1 (Pbx1) transcription factor have 
been reported to be necessary for adrenal development.  In the case of Cited2, 
null mice demonstrate complete adrenal agenesis and other developmental 
defects [19].  It has been since shown that Cited2 interacts with Wt1 to modulate 
Sf1 dosage and maintain the proper threshold of gene expression necessary for 
adrenal development [20].  The Pbx1 gene product has also been shown to be 
necessary for normal adrenal development, as Pbx1 mutant mice have greatly 
reduced Sf1 expression and the complete lack of adrenal glands [21].  It has 
recently been shown that Pbx1 interacts with Hox and Prep1 to form a 
transcriptional complex that is capable of regulating the fetal expression of Sf1 
unique to the fetal X-zone cells. [22].  Finally, the same report by Zubair et. al. 
demonstrates that Sf1 itself is involved in an auto-regulatory loop that is initiated 
following fetal expression of Sf1 under the regulation of the Pbx1-Hox-Prep1 
complex, together defining the fetal enhancer (FAdE) of Sf1.  At approximately 
E14.5 in the mouse adrenal, Sf1 expression is believed to shift from being driven 
by FAdE in the fetal cortex to being dependent upon a definitive, adult cortical 
enhancer (DAdE) that has yet to be defined.  Lineage tracing experiments prove 
that adult cortical cells expressing Sf1 under the control of DAdE are derived 
from cells once expressing Sf1 via the FAdE enhancer [23].  These data have led 
to the current hypothesis that the adrenal cortex is maintained throughout life by 
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a population of putative stem or progenitor cells in the adrenal capsule that are 
derived from the early fetal cortex.            
 The concept of adrenal turnover and regeneration is not novel.  In 1883 
Gottschau proposed a theory of cellular migration in the adrenal cortex that has 
been experimentally supported over the years.  Proliferation has been primarily 
observed in the outer periphery of the cortex, as enucleation (removal of the 
inner cell mass of the adrenal while leaving the outer capsule intact) results in the 
gradual regrowth of the adrenal cortex from the remaining capsule and peripheral 
cortical tissue, complete with functional zonation [24-26].  In addition to 
enucleation experiments, transplantation studies of the adrenal cortex also 
support the concept of continued cortical turnover and replenishment.  
 Until recently, however, the evidence for a population of adrenal stem or 
progenitor cells, and the molecular mechanisms that maintain this population has  
been sparse.  Several reports published within the last five years have generated 
evidence that the Sonic hedgehog (Shh) signaling pathway may play a role in 
these putative adrenal stem or progenitor cells.  The sonic hedgehog signaling 
pathway is involved in the development of numerous vertebrate organ systems 
[27].  Recent studies have shown that Shh ligand is expressed in the cortical 
subcapsular region.  Ablation of Shh in the adrenal cortex results in decreased 
cortical size and proliferation, suggesting that Shh is necessary for the 
maintenance of the cortex [28-30].  Insight into the role of these Shh expressing 
cells comes from the elucidation of cells that respond to Shh, and hence express 
the downstream effector of the sonic pathway, Gli1.  Interestingly, Gli1 expression 
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is restricted to the cells of the outer capsule of the adrenal gland, and is not 
expressed in the underlying cortex.  Furthermore, these Gli+ cells can be lineage 
traced to Sf1 expressing cortical cells and indeed give rise to fully differentiated 
cells of the cortex.  These specific studies by Ching & Vilain, King et. al., and 
Huang et. al. provide evidence that Gli1+/Shh-/Sf1- cells in the capsule give rise 
to an undifferentiated Shh+/Gli- subcapsular cell before becoming fully 
differentiated Sf1+/Shh-/Gli- definitive cortical cells [28-30].  Taken together, 
these data suggest both a signaling and cell lineage relationship between Shh 
expressing subcapsular cells and Gli1 expressing capsular cells that underlies 
the homeostatic maintenance of the adrenal cortex.          
 In addition to the Shh signaling pathway, other molecular mechanisms 
have been implicated in adrenal maintenance.  The Wnt/β-catenin pathway is 
involved in the adrenal gland during development, and is critical for the 
maintenance of the adult cortex.  Loss of β-catenin in the adrenal cortex during 
development results in complete adrenal aplasia, and continuous impairment of 
the Wnt/β-catenin signaling pathway in adult mice results in the gradual failure of 
adrenocortical replenishment and maintenance [31].  Similarly, the dosage-
sensitive sex reversal, adrenal hypoplasia congenita (AHC) critical region on the 
X chro- mosome, gene 1 (Dax1) gene is an orphan nuclear receptor that 
functions primarily to repress Sf1-mediated transcription in peripheral cortical 
progenitor cells to maintain the adrenocortical stem/progenitor population.  
Humans with mutations in DAX1 manifest clinically with adrenocortical failure due 
to adrenal hypoplasia or aplasia, and mice lacking the gene exhibit a gradual 
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decrease in adrenal proliferation and steroidogenesis [32].  Interestingly, Wnt 
signaling has been shown to induce Dax1 transcription, supporting the notion 
that adrenocortical maintenance and regeneration is under the control of a 
complex regulatory network of numerous signaling and transcription factors [33].  
Adrenal Neoplasms
 The relationship between physiologic tissue regeneration and pathologic 
tumorigenesis has long been recognized, and the adrenal cortex is no different in 
this regard.  Adrenal masses are relatively common in the general population, 
with an incidental detection rate of up to 10% [34].  There are numerous types of 
adrenal neoplasms that include metastases from other tumors and those 
originating from non-adrenal cell types such as myelolipomas or lymphomas.  
However, the three types tumor types arising from adrenal restricted cell 
populations are adrenocortical adenomas (ACA), adrenocortical carcinomas 
(ACC), and pheochromocytomas.  ACAs, by virtue of their nomenclature, are 
generally benign, and account for up to 80% of adrenal neoplasms [34].  
Pheochromocytomas are neoplasms of the adrenal medulla, and are often 
characterized by a clinical presentation consistent with excessive catecholamine 
production and can be detected by elevated serum and urinary catecholamine 
metabolites (metanephrins).  For both ACAs and pheochromocytomas, surgical 
resection is often curative, and patients generally have good prognoses.  In 
sharp contrast, ACCs represent an extremely small fraction of all adrenal 
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neoplasms on an annual basis, yet the clinical outcome for patients diagnosed 
with ACC is usually poor.  
 Adrenocortical carcinomas have a reported incidence ranging from 0.5-2 
cases per million per year.  This represents less than 1% of all annually reported 
cancers.  ACC is an aggressive cancer, and most cases are relatively advanced 
when diagnosed, contributing to a 5 year survival rate of less then 10% [35].  
Treatment options for ACC are limited, and ACCs are often unresponsive to 
standard chemotherapeutic agents [36].  Surgical resection is typically the 
treatment of choice for localized disease, and adjuvant therapy with mitotane 
(o,p’-DDD; an isomer of the insecticide DDD which is derived from DDT) is often 
utilized to prevent recurrence in patients.  Unfortunately, the effectiveness of 
mitotane is limited by its toxicity [37], and while additional strategies including the 
addition of streptozocin to adjuvant therapy, or the use of an etoposide, 
doxorubicin, and cisplatin (EDP) based therapy for non-operable disease have 
helped increased survival, the need for more targeted ACC treatments still 
remain [38,39].
 The genetic mechanisms that drive the development of ACC have been 
the subject of recent study, and may hold the key to developing novel treatment 
strategies for this disease.  There are several genetic causes of ACC that have 
been described over the years, and are often associated with disease 
syndromes.  Mutations that render the TP53 tumor suppressor gene inactive, 
which define the Li-Fraumeni syndrome, can predispose affected individuals to a 
higher risk of developing ACC and other types of cancer [40].  The multiple 
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endocrine neoplasia type I syndrome (MEN1) involves genetic abnormalities in 
the MEN1 gene, a putative tumor suppressor.  Patients diagnosed with this 
autosomal dominant syndrome variably develop parathyroid pituitary, pancreatic, 
and occasionally, adrenal tumors [35,41].  The Wnt/β-catenin signaling pathway 
is also implicated in adrenal development and tumorigenesis [31,42].  Mutations 
in the APC gene, which negatively regulates β-catenin (CTNNB1), are known to 
predispose affected patients to familial adrenal neoplams, although these often 
tend to be non-malignant adenomas [43].  In contrast, mutations in CTNNB1 
itself that render it insensitive to regulatory factors are described primarily in 
cases of sporadic adrenal tumors which are also typically benign, suggesting 
mutations in APC or CTNNB1 alone may not be sufficient to drive the formation 
of ACC [44].  However, cases of ACC that demonstrate APC or CTNNB1 
mutations are correlated with poorer outcome and shorter disease free survival 
[45].  The most common genetic abnormalities seen in sporadic ACCs, however, 
are those in the locus that encodes the insulin-like growth factor 2 (IGF2) gene.  
Beckwith-Wiedemann syndrome (BWS) is characterized by a loss of imprinting 
defect at the 11p15.5 locus containing the IGF2, p57KIP2 (CDKN1C), and H19 
genes, and results in excessive IGF2 expression and decreased CDKN1C and 
H19 expression.  CDKN1C is a cyclin-dependent kinase inhibitor, and negatively 
regulates cell cycle progression.  H19 encodes a 2.3 kb non-protein coding 
transcript whose function remains unknown.  It is thought to potentially act as a 
tumor suppressor, and is able to decrease IGF2 transcript levels in vitro [46].  
BWS is characterized by macrosomnia, macroglossia, organomegaly, ear and 
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renal abnormalities, and an increased incidence of childhood tumors including 
ACC [35,47].  Normally IGF2 is expressed from the paternal allele, while 
CDKN1C and H19 are expressed from the maternal allele.  In BWS, IGF2 can be 
expressed from both alleles, or CDKN1C and H19 expression may be silenced 
entirely due to epigenetic or genetic defects at the 11p15.5 locus that alter the 
relative contributions of each allele [47].  Similarly, sporadic ACCs are often 
associated with genetic defects at the 11p15.5 locus, with increased IGF2 
expression and concomitant down-regulation of CDKN1C and H19 [48].  In more 
recent studies utilizing microarray analysis on human ACC samples, IGF2 is 
confirmed as being consistently among the most highly up-regulated transcripts 
in ACC versus normal adrenals or even adrenal adenomas [49-52].  Furthermore, 
increased IGF2 expression is also correlated with increased malignancy of 
adrenal tumors [53].    
 Although there is overwhelming evidence implicating IGF2 expression in 
the development of ACC, the exact role of IGF2 in ACC is still not fully 
understood.  Both IGF1 and IGF2 are known to play important roles in the 
development and differentiation of the normal adrenal gland.  IGF receptors, IGF 
binding proteins, and the IGF1/IGF2 peptides are synthesized in the adrenal 
glands of a variety of species, and have mitogenic effects on adrenocortical cells 
in vitro and in vivo.  These effects are mediated through the activity of the IGF1 
receptor (IGF1R), which is expressed in both the normal adrenal and in ACC cell 
lines such as NCI-H295R [46,51].  However, while postnatal mice engineered to 
over-express Igf2 exhibit increased adrenal weight, they do not develop ACC 
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[54].  Similarly, other mouse models engineered to increase Igf2 expression and 
decrease the function of either H19 or Cdkn1c fail to develop ACC, despite the 
fact that they more closely recapitulate clinical features of BWS [55,56].  These 
reports suggest that neither increased Igf2 expression nor dysregulation of the 
11p15.5 locus alone are sufficient to cause ACC.  Therefore, other genetic 
defects must also be present.  Recent work from our lab provides evidence of a 
synergistic role for defects in both the Wnt/β-catenin signaling pathway and Igf2 
locus, supporting a genetic “multi-hit” progression leading to the development of 
ACC.  Research into the genetic causes of ACC has led to the investigation of 
new therapeutic targets in this rare yet aggressive cancer.  Recent work on IGF2 
signaling in ACC has led to the initiation of clinical trials for drugs targeting this 
pathway, which show significant promise [51,57].  Additional research may yet 
provide ACC patients with new, effective treatments for this disease. 
                          
MicroRNAs
 The first microRNA (miRNA) was described by Lee et. al. in 1993, when 
the heterochronic C. elegans gene lin-4 was found to encode small RNAs with 
complementary sequences to the 3’ untranslated region (UTR) of the lin-14 gene 
transcript [58,59].  At the time, this observation remained largely a novelty of post 
transcriptional gene silencing in the nematode, and these small RNAs were 
initially referred to as small temporal RNAs (stRNAs) due to their temporally 
regulated expression and their role in regulating developmental timing [60].  It 
quickly became evident that these newly described stRNAs functioned in a post-
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transcriptional gene silencing (PTGS) role, and had some aspects in common 
with PTGS phenomena that had been previously observed in plants.  
 PTGS had been described in plants, when it was observed that 
transgenes introduced into petunias with the intent of over-expressing an enzyme 
necessary for flower pigmentation had the opposite effect [61].  Although what 
Napoli had reported was eventually recognized as a specific type of PTGS 
known as RNA interference (RNAi), it was not until later in the decade that Fire 
and Mello described this phenomenon in greater detail [62].  In the years 
following the discovery of lin-4 in nematodes, similarities between these new 
stRNAs (now known as miRNAs) and the RNAi pathway were noted.  For 
example, the ~22 nucleotide length of mature stRNAs was recognized to be 
nearly identical to that of RNAs involved in RNAi [63,64], and the downstream 
genes and mechanisms necessary for proper processing of RNAs destined for 
RNAi mediated gene repression appeared to be shared by stRNAs.  For 
example, both RNAi and stRNAs were soon demonstrated to require the activity 
of Dicer, an RNase III enzyme, and both also require a class of proteins known 
as Argonautes, which catalyze their PTGS activity [65].  However, researchers 
also observed several key differences that suggested that despite their 
similarities, RNAi and stRNAs were two distinct pathways.  First, RNAi was 
described as primarily the result of exogenously supplied double stranded RNA 
molecules, while stRNAs were derived from the organism’s genome [62].  
Second, RNAi was shown to induce degradation of target mRNA transcripts 
[63,66], while stRNAs were initially described as inducing translational repression 
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[67].  Finally, lin-4 does not form perfect duplexes with its cognate target, lin-14 
[68], unlike RNAs involved in the RNAi pathway which typically rely on perfect 
sequence complementarity with their targets [69].  
 Seven years following the discovery of the lin-4/lin-14 relationship in 
nematodes, several breakthroughs were reported in the field of both RNAi and 
miRNAs.  The RNA directed effector protein complex (RNA Induced Silencing 
Complex [RISC]) and RNase III enzyme (Dicer) required for RNAi were 
described, which allowed researchers to better characterize the mechanistic 
similarities between RNAi and miRNA mediated gene silencing described above 
[64,70-72].  Additionally, a second miRNA was discovered.  In 2000, the 
heterochronic regulatory RNA, let-7, was discovered and described in detail, 
including its conservation across the animal kingdom [60,73,74].  This confirmed 
that miRNAs were not simply a curiosity in nematodes, but belonged to a post 
transcriptional gene silencing pathway that is conserved through metazoan 
evolution.  Within one year, miRNAs were recognized as a distinct subclass of 
non-coding, phylogenetically conserved RNAs within the genome [75], and 
reports describing additional miRNAs began to accumulate [76-78].  It was 
collectively agreed by leading researchers of the emerging miRNA field to refer to 
this new subclass of RNAs as miRNAs, displacing the previously used 
terminology of heterochronic and small temporal RNAs.  By the end of the 
decade, the field of miRNAs had expanded exponentially, and today, our 
understanding of their functions in development, physiology, and disease 
continues to grow.  Current research has shed significant light on the 
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evolutionary and genomic origins of miRNAs, their cellular biogenesis, and the 
mechanisms by which they repress the expression of target genes.  As discussed 
in the subsequent sections of this introduction, it is now known that miRNAs are 
expressed from endogenous loci within the genome of an organism, and function 
by inducing the degradation of target mRNA transcripts to repress gene 
expression.  Furthermore, miRNAs can affect multiple target genes, and are 
therefore closely integrated in gene regulatory networks as a result of this 
pleiotropism.  miRNA biogenesis has also been demonstrated to be necessary 
for the embryologic development in mammals, and specific miRNAs are capable 
of regulating physiologic processes such as cell renewal and differentiation.  
Finally, miRNAs have been implicated in the regulation of disease processes, 
particularly the development of human cancers.  As discussed in this 
introduction, miRNAs can act as both tumor suppressors and oncogenes by 
regulating gene transcripts that are responsible for mediating tumorigenesis, and 
recently, have shown promise in their use as prognostic markers in human 
cancer.
MicroRNA Biogenesis
 Micro-RNAs are derived from endogenous loci within the genome of an 
organism and undergo progressive processing steps to form a mature miRNAs 
(Figure 1.4).  The majority of mammalian miRNAs can be found in clusters of 
functional transcriptional units.  Approximately 80% are transcribed from intronic 
regions of either protein or non-protein coding transcriptional units, while a 
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minority may be found in exons [79-82].  Additionally, many mammalian miRNAs 
have multiple paralogues of each other, presumably due to gene duplications that 
occurred during the phylogeny of the organism [82].  These paralogues often 
have identical sequences in the “seed” region (positions 2-7 relative to the 5’ end 
of the miRNA) and are therefore thought to be redundant, although differential 
expression in vivo may suggest distinct roles for these various isoforms [83].  
Biogenesis of miRNAs requires multiple processing steps of the initial miRNA 
transcript, and is under multiple layers of regulatory control [84,85].  
 miRNAs are primarily transcribed by RNA polymerase II (Pol II) and many 
primary transcripts are capped and polyadenylated, characteristic of Pol II 
transcription [86-89].  However, a  small number of miRNAs can be transcribed 
by RNA polymerase III [90].  The use of Pol II allows for the control of miRNA 
transcription by the range of Pol II associated transcription factors.  For example, 
p53 and the Tcf/Lef transcriptions factors associated with Wnt/B-catenin signaling 
are able to directly regulate transcription of miR-34 and miR-483, respectively 
[91,92].  As a result, miRNAs transcribed by Pol II can be specifically regulated 
under a number of conditions and cell types.      
 The primary miRNA transcripts (pri-miRs) generated by RNA polymerases 
can vary in length from several hundred bases to several hundred kilobases and 
carry local stem loop structures [86,93].  The first step in the canonical miRNA 
processing sequence involves endonucleolytic cleavage at the stem of the 
hairpin structure, which releases a small hairpin known as a precursor miRNA 
(pre-miR).  This process is mediated by the Microprocessor complex, a putative 
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650kD multimeric protein complex which includes the RNAse III enzyme Drosha 
[94,95] and the dsRNA binding protein Dgcr8 [96,97].  The Microprocessor 
recognizes potential pri-miRs for processing by the single stranded RNA 
sequences that flank the ~33bp stem of the hairpin structure.  Dgcr8 interacts 
with this portion of the pri-miR, and in conjunction with Drosha, cleaves 11 base 
pairs away from the single strand/double strand junction at the hairpin base [98].  
The Microprocessor complex itself is under complex regulation, including an 
auto-regulatory loop whereby Drosha cleaves its own co-factor, Dgcr8 [99].  
Additional regulation at this point in the miRNA pathway has been attributed to 
transforming growth factor beta (TGF-β) and bone morphogenic protein (BMP) 
signaling.  It has been demonstrated that following signaling by BMPs or TGF-β, 
activated downstream Smad proteins can increase the recruitment of pri-miRs to 
the Microprocessor complex, enabling more efficient cleavage by Drosha.  This 
mechanism is believed to occur in part by the ability of Smad1, 3, and 5 to bind a 
nucleotide sequence in the stem structure of specific pri-miRs that resembles the 
consensus sequence recognized by the Smad DNA binding domain.  Additionally, 
activated Smads can also directly bind to the RNA helicase p68, a subunit of the 
Microprocessor complex; this interaction is required for Smad mediated pri-miR 
processing.  Although miR-21 and miR-199a were among the first miRNAs 
described to be subject to this regulatory mechanism, subsequent studies have 
demonstrated numerous other miRNAs that can respond to BMP/TGF-β 
signaling in this manner [100,101].  
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 Following Drosha mediated cleavage, the pre-miRNA is then transported 
out of the nucleus by Ran-GTP and the Exportin-5 nuclear transport protein 
[102].  The pre-miR sequence is inconsequential for recognition by Exportin-5, as 
the length of the hairpin and 3’ overhangs appear to be sufficient [103].  Once in 
the cytoplasm, another RNAse III enzyme, Dicer, in complex with the 
transactivator RNA (tar) binding protein (TRBP) [104], cleaves the hairpin loop 
from the stems.  The resulting ~22 nucleotide Dicer-Trbp bound RNA duplex is 
then joined by an Argonaute (Ago) protein, and a glycine tryptophan repeat 
containing 182kD protein (GW182) to generate the miRISC effector complex.  
One strand of the ~22 nucleotide duplex is retained as the guide strand or mature 
miRNA.  The other strand is referred to as the passenger strand or miRNA* 
(miRNA “star” strand) and is degraded.  Generally, selection of which strand 
becomes the miRNA* is dependent on the relative thermodynamic stability of the 
two ends of the duplex.  The strand with the less stable 5’ end is retained, while 
the other becomes the miRNA* strand [105].  Once incorporated into the Ago-
RISC complex, a mature miRNA is then able to exert its post-transcriptional 
regulatory effects on target mRNAs.  Due to the partially complementary binding 
between miRNAs and target sequences in the 3’ UTR of mRNA transcripts, it is 
possible for a given miRNA to potentially target and bind to multiple mRNAs 
[106,107].  This phenomenon has the effect of allowing a single miRNA to have 
potentially pleiotropic downstream effects, and complicates the identification of 
mRNA targets.  In metazoans, miRNA binding sequences almost invariably 
reside in the 3’ UTR of target transcripts, and are often present in multiple copies.
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 Recent reports suggest some miRNAs can be generated through several 
non-canonical pathways.  For example, a number of intronic miRNAs known as 
“mirtrons” have been shown to mature without Drosha mediated cleavage if they 
are of the proper size to form a hairpin consistent with a pre-miR.  In this case, 
the hairpin consists of the entire host intron and bypasses Drosha mediated 
cleavage.  Instead, mRNA splicing is responsible for the first step of biogenesis, 
and the pre-miR is excised as an intronic lariat structure that is subsequently 
linearized, then exported directly to the cytoplasm for further downstream 
processing by Dicer.  These mirtrons are characterized by flanking sequences 
that correspond to the 5’ splice site if a 5’ miRNA is formed, or the 3’ splice site if 
a 3’ miRNA is formed [108,109].  This is in contrast with canonical intronic 
miRNAs, which still require subsequent processing by Drosha following 
transcription to form a pre-miR that can be exported to the nucleus for Dicer 
processing.  Mirtrons have subsequently been described in additional organisms 
including mammals, plants, and avians using deep sequencing techniques 
[110-112].  More recently, additional miRNA biogenesis pathways have been 
described in mammalian cell lines.  Three independent reports were published in 
the summer of 2010 that describe the biogenesis of miR-451, an unusually highly 
conserved miRNA shown to be important for erythropoiesis [113].  Further 
investigation into miR-451 demonstrates that its maturation is dependent on the 
endonuclease activity of Ago2, and is refractory to Dicer inactivation [114-116].  
The implications for this are significant, as miR-451 is perfectly conserved in 
vertebrates, suggesting that the retention of Ago2’s unique catalytic activity 
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among the mammalian Argonaute proteins may be evolutionarily constrained to 
maintain this non-canonical miRNA biogenesis pathway.  Additionally, Yang et. al. 
also demonstrate the ability of a reprogrammed miR-451 backbone to confer 
Dicer independent expression of other miRNAs, a feature which could show 
promise as a molecular tool to aid in the study of miRNAs [115].  Finally, a recent 
report by Havens et. al. claims to have identified yet another non-canonical 
miRNA biogenesis pathway, in which the biogenesis of the predicted mirtrons 
miR-1225 and miR-1228 is independent of most of the canonical miRNA 
biogenesis components, including Dgcr8, Dicer, Exportin-5, or Ago2 [117].  
Instead, the authors report that Drosha appears to be the only component 
required for the maturation of these miRNAs, which they term splicing-
independent mirtron-like miRNAs (simtrons).  However, the authors were unable 
to identify the binding partners and additional components of this newly 
described simtron biogenesis pathway, and further research is necessary to 
elucidate this novel mechanism.  
MicroRNA Mediated Silencing Mechanisms
 The canonical miRNA mediated gene regulatory pathway requires the 
binding of mature miRNAs to their cognate mRNA targets through partially 
complementary sequences in the mRNA’s 3’ UTR.  There are several 
experimentally and bioinformatically defined rules involving miRNA-mRNA 
interactions [118,119].  First, positions 2-7 (the seed region) must generally be 
continuous and perfectly matched, as mismatches in this sequence greatly affect 
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miRNA mediated repression; second, bulges or mismatches must be present in 
the central region of the miRNA to preclude endonucleolytic cleavage by Ago2; 
finally, there must also be partial complementarity in the 3‘ end of the miRNA to 
ensure stability [119-121].  Although these factors are not exhaustive in 
describing miRNA-mRNA interactions, they are considered to be among the most 
important.  Recently, it has been demonstrated that bulged pairing at nucleotide 
positions 5-6 in the miRNA-mRNA pair can in some instances provide enough 
stability for the propagation of the seed interaction [122].  This observation, which 
was primarily seen in the mouse brain, has the potential to expand the number of 
predicted miRNA binding sites that would need to be considered when 
performing target prediction analyses.  
 Since their discovery in 1993, the mechanism by which miRNAs are 
thought to inhibit their mRNA targets has been a controversial subject.  Evidence 
supports the possibility of both transcriptional degradation and/or translational 
repression, (Figure 1.5) and initially, miRNAs were thought to primarily function 
through the latter mechanism [123,124].  Indeed, this was recognized as one of 
the hallmark differences between canonical RNAi and miRNA mediated 
repression in plants, both of which are primarily characterized by degradation of 
the transcriptional target.  There have been four distinct methods proposed to 
explain miRNA mediated translational inhibition in animals: inhibition of 
translational initiation, inhibition of elongation, co-translational protein 
degradation, and premature termination of translation [123,124].     
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 Translation of mature mRNAs into protein broadly falls into 3 discrete 
stages:  Initiation, elongation, and termination.  The majority of miRNA mediated 
mRNA decay mechanisms involve perturbation of the initiation and elongation 
steps [118,125].  Additionally, miRNAs have been reported to facilitate the 
destabilization of target mRNAs through removal of the m7G cap (decapping) 
[126,127] and the poly A tail (deadenylation) [128-130].  In the initiation stage of 
eukaryotic translation, the eIF4E subunit of the eukaryotic translation initiation 
factor (eIF4) binds to the m7G cap at the 5’ end of the mRNA.  The other subunits  
in eIF4 recruit and stabilize the 40S ribosomal subunit.  At the 3’ end, 
polyadenylate binding protein 1 (PABP1) binds to the poly A tail of the mRNA, 
and in turn binds to the eIF4G subunit of eIF4.  In doing so, the mRNA becomes 
circularized, and translation is initiated.  Elongation can then begin when the 60S 
ribosomal subunit joins the protein complex at the AUG start codon [131].  
 Inhibition of translational initiation by miRNAs is thought to involve the 
Argonaute proteins that are bound with mature miRNAs as part of the RISC.  It 
has been shown that human AGO2 has sequence similarities with the eIF4E 
translation initiation factor subunit that binds to the m7G cap of mRNAs to begin 
the initiation process.  In addition, AGO2 is able to bind a sepharose bound m7G 
analog in vitro and suggests that binding of AGO2 to the m7G cap can displace 
eIF4 factors and prevent initiation [132].  Both cell culture and cell free systems 
supported this notion, and also showed that non-cap dependent translation 
driven by an internal ribosomal entry site (IRES) was not silenced by miRNAs 
[126,127,133].  Subsequent studies in the fly and nematode also provided 
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evidence that the miRNA silencing machinery targets the mRNA cap structure or 
interferes with the cap binding complex [134,135].  In addition, Chendrimada et. 
al. reported that eIF6 and the 60S ribosomal subunit co-immunoprecipitate with 
AGO2 and other miRISC components [136].  By binding eIF6 and its associated 
60S ribosomal subunit, AGO2 may be able to prevent the association of the small 
and large ribosomal subunits, inhibiting initiation.  However, this is a controversial 
subject regarding miRNA mediated translational inhibition, as  Eulalio et. al. 
demonstrated in a subsequent report that eIF6 does not appear to be required for 
miRNA mediated silencing [137].
 Experimental evidence also supports the notion that miRNAs can repress 
target mRNAs at the post-initiation or elongation stages of translation.  Early 
experiments in C. elegans showed that miRNA targets remained associated with 
polysomes despite a marked reduction in protein expression [67,138].  Other 
experiments in mammalian cells involving sucrose sedimentation experiments 
supported the theory that miRNAs may be blocking elongation at a later 
translational stage following initiation [139-141].  These studies showed that 
miRNAs appeared to associate with their mRNA targets undergoing translation, 
but without the protein product being detectable.  To explain these results, 
Nottrott et. al. [140] proposed a model of co-translational degradation, where the 
nascent polypeptide is degraded as it exits the ribosome.  In contrast, Petersen 
et. al. [141] suggested that miRNAs might induce the premature termination of 
translation, resulting in the drop-off of ribosomes from the target transcript, 
resulting in an incomplete and unstable polypeptide.
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 In yet another mechanism, miRNAs have been shown to induce the 
degradation of their mRNA targets, complementing their reported ability to induce 
translational repression.  In plants, mRNA target degradation is believed to be the 
most common mechanism of miRNA mediated gene silencing, similar to the 
mechanism seen in RNAi.  In contrast, animal miRNAs, until recently, were 
thought to repress targets mainly through translational inhibition, as outlined 
above.  However, earlier studies reported the ability of animal miRNAs to 
degrade their cognate mRNA targets [142-144], raising the possibility that 
miRNA mediated mRNA degradation might be more common in animals than 
originally thought.  In eukaryotes, mRNA degradation follows two primary 
pathways which are both initiated by a shortening of the poly A tail.  Following 
this deadenylation step, mRNAs can be degraded 3‘ to 5‘ by the exosome, or 
degraded 5‘ to 3‘ following removal of the m7G cap [145].  It has been shown that 
miRNA mediated mRNA degradation in animals is dependent on the 5’ to 3’ 
mRNA decay pathway in which they are first deadenylated [128,129,146,147].  
This deadenylation step appears to be facilitated by the CAF1-CCR4-NOT 
deadenylase complex, which is required for miRNA mediated deadenylation as 
depletion of these components results in the up-regulation of miRNA targets 
[146,148,149].  Genome-wide studies with the goal of determining the 
contribution of both translational repression and transcriptional degradation to 
miRNA mediated gene silencing have shown that animal miRNAs have only a 
modest effect on the translation of mRNA transcripts [150] [151].  More recently, 
Guo et. al. demonstrated using ribosomal profiling techniques in mammalian cells  
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that ≥84% of miRNA mediated repression occurs due to mRNA transcript 
destabilization, while only a small fraction of repression is due to reduced 
translational efficiency [152].  These data together support the notion that 
mammalian miRNAs function primarily at the mRNA transcript level, and have 
minor effects on protein synthesis.  Furthermore, in cases where translational 
inhibition does occur, it appears to do so at the translational initiation stage 
[152,153].  These observations are inconsistent with the previously proposed 
models of nascent polypeptide degradation or premature ribosomal drop-off. 
 Despite these advances made in delineating the roles of translational 
repression and mRNA degradation in miRNA mediated gene silencing, the 
temporal order of miRNA mediated silencing is still being elucidated.  Recent 
studies now support a more parsimonious model that is able to unify the 
observed miRNA mediated gene silencing mechanisms of translational inhibition 
and mRNA degradation.  These reports provide data that suggest miRNAs 
initially inhibit translation of their target mRNAs, but then subsequently induce 
degradation of the mRNA transcript [154-156].  Research into the GW182 
protein, a core component of the miRISC, has demonstrated its ability to mediate 
both translational repression and deadenylation of target mRNAs [157].  Indeed, 
it was observed in earlier reports that GW182 is critical for miRNA silencing, as 
depleting this protein abrogates miRNA activity [137,158].  It is now believed that 
GW182, through its C-terminal “silencing domain” facilitates in part the silencing 
effects of miRNAs by interacting with poly-A binding proteins (PABP) and 
recruiting the CCR4-NOT deadenylase complex (reviewed in [159])     
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Emerging Role of MicroRNAs in Development & Cancer
 Since their discovery in 1993, miRNAs have been implicated in 
developmental processes, as lin-4 null nematodes exhibit developmental defects 
consistent with inappropriate lin-14 expression [58,59].  Given the ubiquitous and 
highly conserved nature of miRNAs, it is therefore not surprising that miRNAs 
play critical roles in the developmental regulation of higher organisms.  The first 
Dicer KO mouse was described by Bernstein et. al. in 2003 [160].  In this mouse 
model, the authors report that loss of Dicer in the developing mouse is embryonic 
lethal at approximately embryonic day 7.5 (E7.5), and is accompanied by loss of 
embryonic stem cells (ES cells) in mutant embryos.  Indeed, subsequent studies 
have confirmed the role of Dicer in regulating pluripotency and differentiation of 
stem cells in various models [161-163].  Since then, numerous tissue specific 
knockout models in the mouse have confirmed the importance of Dicer in the 
development of various organ systems [164-170].  The necessity for Dicer, and 
presumably miRNA biogenesis, through the course of organismal development is  
irrefutable.  However, the subsequent steps to further understand this 
observation involve uncovering the underlying mechanisms of specific miRNAs in 
the development of the organism.
 Another rapidly advancing area of research involving miRNAs is the 
investigation into their role in disease processes, especially tumorigenesis.  It has  
been established that genetic mutations that perturb the miRNA biogenesis 
pathway are implicated in tumorigenesis.  Mutations in TRBP2 not only impair 
miRNA biogenesis, but have also been identified in sporadic and hereditary 
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carcinomas [171], as have inactivating mutations in Exportin-5, which result in 
the trapping of pre-miRNAs in the nucleus to inhibit miRNA biogenesis [172].  
Also, several reports within the last year have emerged that describe 
heterozygous loss of function mutations of the human DICER gene in the context 
of several familial syndromes.  The patient cohorts studied presented with a 
heterologous pattern of tumors that includes sertoli-leydig cell tumors of the 
ovary, embryonal rhabdomyosarcomas, and pleuropulmonary blastomas 
[173-175].  In addition, sporadic perturbations in DICER expression have been 
reported in numerous cancer types [176-182].  However, until recently, little data 
implicating total DICER loss in tumorigenesis was available.  This was addressed 
in a recent report demonstrating that homozygous Dicer null murine sarcoma 
cells exhibit increased doubling time and higher apoptotic activity compared to 
heterozygous Dicer null cells [183].  When injected into mice, these Dicer null 
sarcoma cells are able to maintain their tumorigenicity, albeit with slight 
impairment compared with heterozygous Dicer null cells.  In this case it would 
appear that complete loss of Dicer activity slightly inhibits tumorigenesis, raising 
the possibility that inhibiting Dicer activity in vivo may hold viable therapeutic use.  
 Individual miRNAs have also been implicated in the process of tumor 
formation and metastasis, with many of them acting as tumor suppressors or 
oncogenes.  The ability of miRNAs to inhibit multiple genetic factors involved in 
tumorigenesis, and the observation that many of these same genetic factors can 
induce the expression of miRNAs has led to the understanding that miRNAs and 
their targets form complex regulatory networks.  In many cases, these networks 
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consist of feed-back and feed-forward regulatory loops, demonstrating that 
miRNAs that integrate themselves into key oncogenic pathways can result in an 
intricate balancing effect between pro- and anti- oncogenic signals.  As a result, 
miRNAs can act as tumor suppressors if they target transcripts that encode 
oncogenic proteins, and conversely, act as oncogenes if they target known tumor 
suppressors.  For example, one of the most closely studied miRNA families, let-7, 
is able to repress several oncogenes including HMGA2, RAS, and MYC 
[184-186], thereby functioning as a tumor suppressor.  Conversely, MYC is able 
to repress let-7 expression [187], and is able to repress the widespread 
expression of other miRNAs [188], including those with anti-tumorigenic and pro-
apoptotic activity such as miR15a/16-1, miR-26, and miR-34 family members 
[187].  In addition, MYC can induce the expression of the miR-17-92 polycistronic 
cluster [189], which has been demonstrated to repress negative regulators of the 
PI3-kinase signaling pathway, and tumor suppressor proteins such as BIM, 
PTEN, and CDKN1A [190-192].  The miRNAs encoded by the miR-17-92 cluster 
are often amplified in lymphoma, small cell carcinoma of the lung [193].  They 
have also been shown to be expressed in developing mouse tissue [194], and 
deletion of the miR-17-92 cluster is embryonic lethal [83], illustrating its role in 
both tumorigenesis and development.   
 Similarly, the network of tumor suppressor proteins in the cell is also highly 
integrated with miRNA input and regulation.  A canonical example is that of the 
regulatory network linking miRNAs and the tumor suppressor gene P53.  The 
expression of miRNAs belonging to the miR-34 family have been demonstrated 
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to be directly induced by P53 [195].  These miRNAs have been shown to 
promote cell cycle arrest, senescence, and apoptosis by negatively regulating the 
expression of proteins that inhibit these processes, and include targets such as 
BCL2 and CDK4 [91].  More recent publications have reported other miRNAs that 
appear to be induced by P53, including miR-192, miR-194, miR-215, and 
miR-605 [196,197].  These miRNAs target MDM2, an important negative 
regulator of P53, suggesting a miRNA mediated feed forward regulatory loop 
initiated by P53 activation.  miR-149* has also been shown to be up-regulated in 
human melanoma in response to P53.  Intriguingly, miR-149* acts as an 
oncogene by inhibiting glycogen synthase kinase 3α and increasing the 
expression of Mcl1, an anti-apoptotic protein that inhibits PUMA, a pro-apoptotic 
protein that is also induced by P53 activation [198].  In contrast, miR-380-5p and 
miR-504 act to repress P53 and promote cellular survival and tumorigenesis 
[199,200].  Likewise, miR-372 and miR-373 have been demonstrated to inhibit 
P53 mediated apoptosis in testicular germ cell tumors [201].  Finally, in an even 
more complex interaction with miRNAs, P53 has been demonstrated to modulate 
miRNA processing through an association with P68 and Drosha [202] that 
promotes pri-miR processing.  In this model, it would be possible for mutant P53 
to interfere with this regulation, and in addition to the direct effects of P53 loss on 
downstream anti-tumor mechanisms, could result in decreased expression of 
cancer relevant miRNAs.  
 Lastly, miRNAs are an area of interest regarding their use as diagnostic 
and cancer therapy tools.  For example, let-7 is often down-regulated in lung 
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cancer [203], miR-196a is up-regulated in pancreatic ductal carcinoma [204,205], 
and miR-483-3p, miR-483-5p, and miR-21 are up-regulated in adrenocortical 
carcinoma [206,207].  Because many miRNAs are uniquely and differentially 
expressed in certain tissues, their expression profiles in conjunction with clinical 
context could be used to determine various qualitative and quantitative 
characteristics of tumors such as tissue of origin, stage, grade, and overall 
outcome.  Further empirical data regarding miRNA expression in various cancers 
is still required, however, and will likely be an ongoing area of study for the 
foreseeable future.  The potential use miRNAs as therapeutic targets has yet 
even more progress that must be made before this concept becomes a practical 
clinical reality.  Currently, molecular tools such as synthetic antisense 
oligonucleotides (antagomirs) designed to inhibit specific miRNAs [142], miRNA 
“sponges” [208], and miRNA mimics that can behave as endogenous miRNAs 
show considerable effect and practicality in many in vitro models, and in the case 
of antagomirs, some success in vivo [209].  However, many challenges remain, 
such as safe and efficient delivery of therapies designed to perturb miRNAs 
involved in a disease state.  Target specificity is another concern, as off target 
effects of miRNA based therapy could have significant side effects in normal, 
healthy tissue given the relative ubiquity of miRNAs and their biogenesis 
pathway.  
       Despite the progress made over the past 20 years in understanding the 
biologic functions of miRNAs, it is clear that much work remains to be completed 
to elucidate mechanisms of miRNA mediated regulation in development and 
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disease.  This work addresses the role of Dicer and miRNA biogenesis in the 
developing mouse adrenal gland, as well as investigating the correlation between 
miR-483-3p and IGF2 expression in human adrenocortical carcinoma.  It is 
hoped that the work described herein will provide novel avenues for further 
research into adrenal miRNA expression and function. 
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Figure 1.1 Histology of mouse adrenal.
Hematoxylin & eosin stain of an adult mouse adrenal gland illustrating the cellular 
zonation characteristic of the adrenal.  The outer-most capsule surrounds the 
gland, and is derived from mesenchymal cells of the stroma around the 
developing gland.  The cortex is further subdivided into the zona glomerulosa 
(zG), zona fasciculata (zF), and zona reticularis (zR).  The zR is not present in 
rodents, but is the source of androgen precursors in primates.  The medulla 
consists of neuroendocrine cells derived from the neural crest, and synthesizes 





Figure 1.2 Steroidogenic pathways of the adrenal cortex
Flow chart illustrating the steroidogenic pathways in each of the cortical zones of 
the adrenal gland.  Mice lack the Cyp17 enzyme, and therefore, cannot produce 
cortisol or precursor androgens.  The predominant glucocorticoid produced by 







































Figure 1.3 Adrenal development in the mouse
Adrenal development in the mouse begins at E9.0 with the coalescence of the 
adrenogonadal primordium (AGP), a bi-potential mass of cells that gives rise to 
both the adrenal cortex and gonads.  The orphan nuclear receptor Steroidogenic 
Factor 1 (Sf1) is detectable in the AGP at this time, and acts as a master 
regulator for adrenal and gonadal development.  Loss of Sf1 results in adrenal 
and gonadal agenesis.  Following the separation of the adrenal and gonadal 
primordia, the fetal cortex begins to coalesce beginning at E10.  Shortly 
thereafter, cells from the neural crest migrate into the developing fetal cortex to 
populate what will become the adrenal medulla.  The adrenal capsule is derived 
from mesenchymal cells in the surrounding stroma, and is hypothesized to be be 
the location in which adrenal stem/progenitor cells reside.  At approximately 
E14.5, the fetal cortex begins to be displaced by the adult or definitive cortex.  
Transcriptional control of Sf1 is believed to shift from the use of a fetal enhancer 
to a still undefined definitive enhancer.  As development progresses, the fetal 
cortex is continuously displaced by the expanding definitive cortex.  In rodents, 
the fetal cortex persists in females until the first pregnancy, whereas in males the 






















Figure 1.4 miRNA biogenesis
Canonical miRNA biogenesis in animals.  miRNAs are found in discrete 
transcriptional units in the genome, often in clusters, and can also be found in 
coding or non-coding regions of protein expressing genes.  Most are transcribed 
by RNA polymerase II, and the resulting primary miRNA is ~70 nucleotide hairpin 
structure that is recognized and cleaved by the Microprocessor complex 
consisting of the Drosha RNase III enzyme and its cofactor, DGCR8.  The 
resulting product is known as a precursor miRNA (pre-miR), and is transported 
out of the nucleus into the cytoplasm via the Exportin-5 nuclear transport protein.  
In the cytoplasm, a protein complex consisting of Dicer, TRBP, and Argonaute 
(AGO) proteins removes the loop from the pre-miR, and helicases unwind the 
duplex.  One strand of the duplex is retained (typically the strand with the less 
stable 5’ pairing) and the other is degraded.  The remaining strand is 
incorporated into the miRNA-induced silencing complex (miRISC), a protein 
complex that facilitates downstream mRNA repression mediated primarily 
Argonaute proteins and the GW182 protein.  The miRISC bound miRNA binds to 
target mRNAs through partially complementary sequences located in the 3’ 




















Figure 1.5 Mechanisms of miRNA mediated post transcriptional gene 
regulation
Evidence for multiple mechanisms of miRNA mediated gene regulation has been 
observed, and the main proposed methods are described here.  miRNAs have 
been demonstrated to induce the destabilization of target mRNAs by the 
deadenylation and subsequent decapping of the target transcript.  Current 
research suggests this is the predominant mechanism in miRNA mediated gene 
silencing.  Additional proposed mechanisms involve translational repression, 
either by preventing the formation of the translational initiation complex, 
proteolysis of the nascent peptide as it exits the ribosome, and inhibition of 
translational elongation.  Current theory holds that miRNAs induce translational 
repression at the initiation step, then subsequently facilitate the degradation of 
target mRNAs.  This parsimonious model helps reconcile the conflicting data 
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CHAPTER 2
Correlation Between MicroRNA-483-3p and IGF2 in Human Adrenocortical 
Carcinoma
 This chapter is comprised of in vitro work performed to establish the 
correlation between IGF2 and miR-483-3p expression in human ACCs.  All work 
was performed independently under the mentorship of Gary Hammer, MD, PhD.  
I would also like to acknowledge Guido Bommer for his assistance in designing 
the miR-483 sponge, and Victoria Kelly for her assistance with luciferase assays.  
Introduction
 Adrenocortical carcinoma (ACC) is a rare yet highly aggressive endocrine 
malignancy, with an incidence ranging from 0.5-2 cases/year per million people, 
and accounts for less than 1% of all reported cancers [1].  Prognosis for patients 
with ACC is unfortunately poor, with a 5 year survival rate of 22% [2].  
Unfortunately, most patients with ACC present with advanced metastatic disease, 
where the 5 year survival is less than 10%, and most cases of ACC present with 
this advanced form of the disease [1].  Treatment options for ACC have 
historically been extremely limited.  Surgical resection is treatment of choice for 
localized disease.  Additionally, radical ACC resection in conjunction with 
adjuvant mitotane therapy and radiotherapy (XRT) has been demonstrated to 
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prolong recurrence-free survival in patients presenting with advanced disease 
[3-6].  However, the benefits of mitotane are relatively modest, and use of the 
drug at therapeutically effective doses is limited by toxicity [5].  While small 
studies suggest some benefits of alternative adjuvant therapies [7], ACC has the 
distinction of being relatively unresponsive to most chemotherapuetic treatments 
[8].      
 There are only a few well characterized genetic causes of sporadic 
adrenocortical tumorigenesis that have been described over the years.  
Inactivating mutations in the TP53 tumor suppressor gene, which is the cause of 
the Li-Fraumeni syndrome, are known to predispose affected individuals to the 
development of ACC, among other types of cancer.  Additionally, mutations in the 
APC gene, which are characteristic of the adenomatous polyposis coli syndrome, 
can lead to the development of adrenal neoplasms, although these tend to often 
be non-malignant adenomas.  The multiple endocrine neoplasia type 1 syndrome 
(MEN1), which is associated with a predisposition towards the development of 
endocrine tumors, is also associated with the formation of adrenal adenomas, 
and to lesser extent, carcinomas [1,8].  The most common genetic abnormalities 
seen in sporadic ACC however, involve those in the locus that encodes the 
insulin-like growth factor II (IGF2) gene.  Nearly 90% of sporadic ACCs are 
shown to have an abnormal up-regulation of IGF2 expression [9], overwhelming 
evidence that supports the association between IGF2 over-expression and the 
development of ACC.  Indeed, the Beckwith-Wiedemann syndrome, which is due 
to a loss of imprinting defect at the 11p15.5 locus that results in excessive IGF2 
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expression, is strongly associated with ACC [10,11].  IGF2 is known to be a 
mitogen for adrenocortical tissue [12], and signals through the ubiquitously 
expressed type 1 IGF receptor (IGF1R), whose expression is also up-regulated 
in many ACCs [13].  Based on this body of work, current therapeutic efforts 
targeting IGF2 signaling in ACC have shown significant promise in clinical trials 
[14,15].
 While IGF2 itself has been implicated in ACC, a microRNA locus, 
miR-483, is located within the 2nd intron of the IGF2 gene.  MicroRNAs 
(miRNAs) are small, endogenous, non-protein coding RNAs that effect post 
transcriptional regulation by targeting partially complementary “seed” sequences 
in the 3’ UTR of target mRNAs.  In conjunction with the miRISC complex, 
miRNAs are able to facilitate the destabilization and degradation of their target 
mRNA transcripts, and repress translation of target mRNAs [16,17].  Although 
initially overlooked, the importance of miRNAs in the regulation of oncogenic 
processes is now widely appreciated.  Perturbations in DICER expression have 
been described in numerous cancer types, with conflicting data on the usefulness  
of over-expression versus under-expression of DICER as a predictor of 
prognostic outcome.  For example, in chronic lymphocytic leukemia, lung, breast, 
and ovarian cancers, lower expression of DICER is associated with poor 
prognosis [18-21].  On the other hand, increased DICER expression is correlated 
with worse outcome in primary cutaneous T-cell lymphomas, colorectal 
carcinoma, prostate cancer, and triple negative breast cancer [22-25].  These 
data suggest the presence of more complicated mechanisms besides simple 
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gain or loss of miRNA biogenesis in tumorigenesis.  Lastly, heterozygous 
germline mutations in DICER have been identified in several familial syndromes 
that are characterized by pleuropulmonary blastoma, multinodular goiter, ovarian 
cancer, and Sertoli-Leydig cell tumors [26-28].
 In addition to perturbations in DICER expression, individual miRNAs have 
recently gained attention for their roles in the pathogenesis of tumor formation.  
Many of the miRNAs identified regulate proliferation, differentiation, or apoptotic 
pathways; these miRNAs have been shown to function as both oncogenes or 
tumor suppressors, and are referred to as ‘oncomirs’ [29-31].  Current research 
suggests that many of these oncomirs hold potential as therapeutic targets or 
prognostic biomarkers indicative of the severity of a tumor [32,33].  
 In this study, we aimed to determine whether IGF2 and miR-483 
expression cold be correlated in human ACC samples and the human ACC cell 
line, H295R.  As previously described, the IGF2 mRNA levels were significantly 
higher in ACC samples compared to normal adrenals [14].  miR-483 transcript 
levels, specifically the miR-483-3p strand, were similarly high in ACCs versus 
normal adrenal tissue samples. To further study miR-483-3p, we constructed a 
lentiviral over-expression vector capable of expressing mature miR-483 at levels 
similar to ACCs and the H295R cell line to aid in the investigation of potential 
miR-483-3p targets and physiologic effects.  Additionally, we tested a luciferase 
sensor and miRNA “sponge” for miR-483 to also aid in pursuing these goals.  We 
were successful in constructing these molecular tools, but were unable to 




 A subset of frozen tissue samples from a larger sample set consisting of 
human normal adrenals (n=3) and both low IGF2 expressing (IGF2-LOW; n=5) 
and high IGF2 expressing (IGF2-HIGH; n=6) ACCs were kindly donated by Dr. 
Thomas J. Giordano, Departments of Pathology and Internal Medicine, University 
of Michigan Medical School, Ann Arbor MI [9].  All patient data were kept strictly 
confidential in accordance with institutional IRB guidelines.
RNA Isolation
 RNA isolation on human tissue samples was performed using a modified 
TRIzol Reagent protocol (Ambion, Life Technologies, Carlsbad, CA).  Briefly, 
following the phase separation step in the manufacturer’s protocol, the aqueous 
phase was removed and subject to an acid phenol chloroform separation step 
using an equal volume of  5:1 phenol:chloroform solution, pH 4.5 (Life 
Technologies, Carlsbad, CA).  After spinning to phase separate the sample, the 
aqueous phase was removed and the RNA was precipitated with 0.5mL 100% 
isopropanol, 1µL linear acrylamide, and 10 µL 3M sodium acetate pH 4.5 (Life 
Technologies, Carlsbad, CA).  Samples were mixed by inversion, then stored at 
-20°C overnight.  The samples were then spun for 10 minutes at 4°C in a 
microcentrifuge to pellet the RNA, then washed with 1mL of 75% ethanol before 
being spun again for 5 minutes at 4°C, and finally resuspended in up to 100µL of 
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nuclease free water.  RNA was quantified on a Beckman DU640 
spectrophotometer.   
Quantitative Real Time PCR for IGF2 and miR-483-3p
 For RNA isolated from human tissue samples, up to 200ng of RNA was 
reverse transcribed using the iScript system (Bio-Rad Laboratories, Hercules, 
CA) to generate cDNA.  The resulting cDNA was diluted 1:5 in nuclease free 
water, and 2µL was used for downstream amplification with appropriate primers 
using Power SYBR Green PCR Master Mix and an ABI 7300 Real Time PCR 
System (Applied Biosystems, Carlsbad, CA).    Data analysis was performed 
using the 2-∆∆C(T) method [34].  Primers for each amplified gene are as follows:  β-
Actin (ACTB) Fwd 5’-CCAACCGCGAGAAGATGA and Rev 5’-
TCCATCACGATGCCAGTG; Igf1 (IGF1) Fwd 5’-TGTGGAGACAGGGGCTTTTA 
and Rev 5’-ATCCACGATGCCTGTCTGA; Igf2 (IGF2) Fwd 5’-
GCTGGCAGAGGAGTGTCC and Rev 5’-GATTCCCATTGGTGTCTGGA; IGF1 
receptor (IGF1R) Fwd 5-‘AAAAACCTTCGCCTCATCC and Rev 5’-
TGGTTGTCGAGGACGTAGAA.  All transcripts were normalized to β-Actin.  
Taqman based miRNA quantitative real time PCR kits for miR-483-3p and U6 
control RNA were purchased from Applied Biosystems by Life Technologies 
(Carlsbad, CA) and used according to the manufacturer’s instructions to 
determine relative expression of miR-483-3p.  Correlation between miR-483-3p 
and IGF2 transcript levels was done using linear regression analysis on 
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miR-483-3p and IGF2 ΔCt values for each sample with the Graphpad Prism 
software suite (La Jolla, CA).
miR-483 Over-expression Vector
 To generate a vector capable of stably expressing miR-483-3p at high 
levels, a 550 base pair product that consisted of the pre-miR-483 hairpin 
structure and 305 and 170 base pairs of flanking sequence upstream and 
downstream, respectively, was amplified using a high fidelity Platinum Taq DNA 
Polymerase from H295R genomic DNA.  The 550bp product was gel purified and 
cloned into a pCRII-TOPO vector using a TOPO TA cloning kit (Invitrogen, 
Carlsbad, CA), then subcloned into the EcoRI restriction site in the MCS of the 
pMSCV-Puro pro-viral vector (Clontech, Mountain View, CA).  The over-
expression vector was confirmed by DNA sequencing (University of Michigan 
Sequencing Core), grown and isolated in  Dh5α E. Coli cells, and transfected into 
the SW13 cell line.  Transfected cells were grown in DMEM supplemented with 
10% fetal bovine serum, antimicrobials, and 3µg/µL puromycin to select for cells 
containing the over-expression vector.  Confirmation of mature miRNA 
expression was assayed with the TaqMan based miRNA assay kit (Applied 
Biosystems) and normalized to U6.
  
miR-483 Sponge
 Biological “sponges” constructed by inserting predicted miRNA binding 
sites has been described previously [35].  Complementary sense and antisense 
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oligonucleotides bearing 3 miR-483-3p binding sites (5’-
AAGACGGGACCTAGGAGTGA-3’; perfect matches in the seed region with a 
non-complementary bulge in the central region of the sequence) in tandem and 
separated by spacers of 4 nucleotides were synthesized and purchased from 
Invitrogen.  The oligos were annealed in vitro to generate a double stranded 
DNA construct with EcoRI compatible sticky ends.  The pLentiLox 3.7 (pLL3.7) 
proviral vector (kindly donated by Guido Bommer) was digested with EcoRI, 
mixed with the DNA insert (sponge) containing miR-483-3p binding sites, and 
annealed using standard molecular cloning procedures.  Insertion and orientation 
of the DNA insert was confirmed with DNA sequencing to ensure that the binding 
sites were properly inserted in the 3‘ UTR of the GFP reporter in the proviral 
vector.  Lentiviral packaging was performed by the University of Michigan Vector 
Core.  H295A and H295R cells were grown in DMEM F12 supplemented with 
10% fetal calf serum, antimicrobials, and L-glutamine.  Cells were transduced 
with 1mL 1x viral supernatant and 8µg/mL polybrene.  After 24 hours, the media 
was replaced with fresh DMEM F12, and the cells monitored for GFP expression.  
Proliferation assays were performed by plating GFP positive H295R cells at a 
starting density of 5x10^5 cells/well in 12 well plates.  Cells were followed and 
harvested on days 1, 2, 3, and 4 (short term) or days 3, 4, 5, and 6 (long term), 
and counted on a hemocytometer.  To assess the transcript levels of the 
predicted miR-483-3p targets IGF1 and EGR1, the SYBR based semi-
quantitative real-time PCR method described in the above section was used.  
Primer sequence for IGF1 was as above, and primers for EGR1 were as follows: 
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Fwd 5’-AGCCCTACGAGCACCTGAC and Rev 5’-GGTTTGGCTGGGGTAACTG.  
Expression data from H295 cells transduced with the miR-483-3p sponge were 
expressed relative to H295 cells transduced with control plasmid.
        
miR-483-3p Sensor Luciferase Assays
 To generate luciferase reporters sensitive to miR-483-3p mediated 
knockdown, a DNA construct consisting of 2 perfectly complementary sites (5’-
AAGACGGGAGGAGAGGAGTGA-3’) to mature miR-483-3p was inserted into 
the EcoRI and SpeI sites downstream of the luciferase reporter in a modified 
pGL3Control plasmid (Promega, Madison, WI).  Insertion was confirmed by DNA 
sequencing.  H295R, H295A, or SW13 cells expressing the miR-483-3p over-
expression vector were plated in 24 well plates at 5x10^4 cells/well.  24 hours 
after plating, cells were transiently transfected and harvested 48 hours later.  
Renilla luciferase (pRL-TK, Promega, Madison, WI) was co-transfected into cells 
and utilized to measure transfection efficiency.  Cell lysates were assayed for 
luciferase activity using the Dual Luciferase Assay kit (Promega, Madison, WI) on 
an auto-injector luminometer.   
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Results
miR-483-3p Expression Correlates Strongly with IGF2 in Primary Human 
ACCs and Human ACC Cell Lines
 We first determined whether IGF2 and miR-483 might be co-expressed in 
ACC.  Previous microarray data from our lab, in collaboration with Dr. Tom 
Giordano (Depts. of Internal Medicine and Pathology, University of Michigan 
Medical School) have shown that increased IGF2 expression in human ACC 
samples contributed to the distinct genetic profile that separated ACCs from 
ACAs and normal adrenals (Figure 2.1).  Further investigation revealed the 
existence of an annotated miRNA, miR-483, located in the second intron of the 
IGF2 gene.  The miR-483 locus, like most miRNA loci, is capable of producing 
two mature sequences, designated by a -3p or -5p suffix, depending on which 
strand of the precursor duplex is selected for miRISC loading.  Given the strong 
correlation between ACC and IGF2 over-expression, we considered whether 
miR-483-3p, the more abundant product of the miR-483 locus, would strongly 
correlate with IGF2 expression and therefore, be characteristic in many cases of 
ACC.  
 Normal human adrenal tissue, and human ACC samples consisting of 
both low and high IGF2 expressing tumors were provided by Dr. Tom Giordano 
as part of our collaboration.  We performed quantitative real time PCR for IGF2, 
IGF1, IGF1R, and ACTB (β-Actin) as an internal normalization control.  
Additionally, numerous human cell lines were also tested for IGF2 expression, 
including the NCI-H295A and NCI-H295R human ACC cell lines.  Figure 2.2A 
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displays the significantly higher expression of IGF2 in human ACC samples 
relative to normal adrenals; the H295A/H295R human ACC cell lines also 
displayed very high IGF2 transcript expression relative to the RL251 cell line, a 
human ACC derived cell line that does not express IGF2.  Also, non-ACC human 
cell lines (HEK293, HeLa, SW13) did not show elevated IGF2 expression.  
Following confirmation of IGF2 over-expression in primary human ACCs and 
human ACC cell lines, mature, endogenous miR-483-3p expression was 
measured in both sets of samples.  TaqMan based quantitative real time PCR 
showed that like IGF2, miR-483-3p expression was significantly up-regulated in 
primary human ACCs, but not normal human adrenals.  Likewise, the high IGF2 
expressing human ACC cell lines H295A and H295R exhibited very high levels of 
endogenous miR-483-3p, whereas the non-IGF2 expressing RL251 cell line did 
not (Figure 2.2B).
 We confirmed the observed correlation between IGF2 and miR-483-3p 
expression in primary human ACCs and human ACC cell lines by performing 
linear regression analysis on the ΔCt values calculated for IGF2 and miR-483-3p 
(relative to internal normalization controls ACTB and U6) for each sample tested.  
Figure 2.3A shows the correlation between IGF2 and miR-483-3p expression 
among primary human adrenal samples, while 2.3B illustrates the same 
correlation in human cell lines.  Both analyses indicate that the correlation 
between IGF2 and miR-483-3p expression is robust, with R2 values of .8021 
and .9683 for primary human ACCs and human cell lines, respectively.  The 
human ACC cell lines H295A and H295R demonstrated similar expression 
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profiles for IGF2 and miR-483-3p, suggesting that these cell lines may serve as a 
convenient in vitro model of IGF2/miR-483-3p high human ACC. 
miR-483-3p Over-Expression Vector 
 Several molecular tools were developed to facilitate further study of 
miR-483-3p and its potential function in the pathogenesis of ACC.  A miR-483-3p 
over-expression vector was developed to allow for stable expression in cell lines.  
In conjunction with sensor reporter constructs and knock-down tools specific for 
miR-483-3p, this construct was designed to facilitate the identification of potential 
mRNA targets, and the isolation of pathophysiologic effects of perturbing the 
level of intracellular miR-483-3p.
 Figure 2.4 illustrates the cloning strategy utilized to generate the 
miR-483-3p over-expression vector.  This expression vector would be predicted 
to express both the -3p and -5p miRNA products; however, we focused our 
analysis on the -3p product due in part to technical limitations of the TaqMan 
qPCR reagents that were available at the time.  In addition to providing robust 
expression of the gene of interest, this vector can be directly transfected into 
cells, or can be packaged into viral particles to transduce cell lines that may be 
difficult to transfect using chemical means.  A similar strategy has been shown 
previously in the past to be effective for the artificial expression of miRNAs [36].  
SW13 (a cell line with low IGF2 expression) cells were transfected with either 
empty pMSCVpuro (pMSCV-Control) or miR-483 expressing plasmid (pMSCV-
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miR483), then grown and passaged in cell culture media containing puromycin to 
maintain selective pressure for transfected cells.    
 We first assessed SW13 cells transfected with pMSCV-miR483 for mature 
miR-483-3p using a TaqMan quantitative qPCR assay specific for mature 
miR-483-3p (Figure 2.5).  SW13 cells transfected with the pMSCV-miR483 vector 
expressed significantly more mature miR-483-3p than control SW13 cells 
transfected with pMSCV-Control vector.  The amount of miR-483-3p expression 
was comparable to what was observed in H295R cells used as positive controls.  
These results indicate that the miR-483-3p expression vector was capable of 
robustly producing mature miRNA transcripts in SW13 cell lines.  Although 
quantitative real time PCR was able to detect mature miR-483-3p in SW13 cells 
transfected with the pMSCV-miR483 vector, it was unknown whether the 
transcripts being produced were functionally active and capable of silencing gene 
targets.
A Luciferase Sensor and GFP ‘Sponge’ for miR-483-3p
 At the time of these experiments, mRNA targets of miR-483-3p were not 
known.  Although the target prediction algorithms used by Targetscan 
(www.targetscan.org) offered significant possible targets with phylogenetically 
conserved miR-483-3p binding sites, the lack of an empirically confirmed target 
made functional studies of miR-483-3p difficult.  This made constructing an 
inhibitor to miR-483-3p challenging as there was no known positive control (i.e. a 
validated, endogenous target 3’ UTR containing miR-483-3p binding motifs) 
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against which we could compare the efficacy of our inhibitor.  To attempt to 
circumvent this limitation, we developed an artificial luciferase sensor construct 
that contained perfect complementary sequences to mature miR-483-3p.  Using 
this approach, it is possible to make miRNAs behave similarly to siRNAs in 
mammalian cells by slightly modifying the 3’ UTR target sequence of a reporter 
construct to be perfectly complementary to the miRNA sequence.  Indeed, 
miRNAs in plants generally exhibit perfect sequence matching between the 
miRNA sequence and target mRNAs.  Additionally, this perfect base pair 
matching commonly leads to the degradation of target mRNAs, characteristic of 
mammalian siRNA and plant miRNA pathways, and may provide a potentially 
greater degree of target inhibition.  
 To generate a miR-483-3p specific luciferase sensor, complementary 
oligonucleotides bearing two repeats of a sequence that perfectly match the 
mature miR-483-3p sequence flanked by EcoRI sticky ends was synthesized 
(See Materials & Methods).  These oligos were then annealed in-vitro and cloned 
into pGL3-Control downstream of the luciferase stop codon and upstream of the 
PolyA sequence.  If both the pMSCV-miR483 expression vector and the pGL3-
Sensor constructs were functioning as intended, decreased luciferase activity 
would be observed in SW13 cells that stably expressed the pMSCV-miR483 
expression vector.  Indeed, SW13 cells expressing miR-483-3p exhibited less 
luciferase activity when the miR-483-3p luciferase sensor was introduced.  In 
contrast, SW13 cells stably expressing the pMSCV-miR483 expression vector did 
not show decreased luciferase activity when pGL3-Control plasmid lacking the 3’ 
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miR-483-3p binding sites was introduced (Figure 2.7).  Likewise, SW13 cells 
stably transfected with the pMSCVpuro-Control plasmid were unable to decrease 
luciferase activity from either pGL3-Control or pGL3-Sensor plasmids.  Taken 
together, these data demonstrate that the miR-483-3p transcript expressed from 
the pMSCVpuro-miR483 vector was able to inhibit a luciferase sensor designed 
to specifically respond to miR-483-3p. 
 The pGL3-Sensor construct was then tested to determine if it would be 
able to respond to endogenous miR-483-3p, as opposed to the artificial 
expression construct utilized in SW13 cells.  pGL3-Sensor or pGL3-Control were 
transfected into both H295A and H295R cells that express high levels of 
endogenous miR-483-3p.  Endogenous miR-483-3p expressed by these cell 
lines was able to significantly decrease the relative measured luciferase activity 
(Figure 2.8).  Interestingly, it appeared that the H295R (295R) cells were more 
effective at repressing the miR-483-3p specific luciferase sensor, as measured 
relative luciferase activity was reduced by up to 3-fold whereas luciferase 
repression in H295A (295A) cells was less than 2-fold.
 In the final part of this series of experiments, a biological sponge was 
designed to “soak” the activity of endogenous miR-483-3p by providing multiple 
miR-483-3p binding sites in a GFP reporter gene.  The rationale behind this 
technique has been described previously, but briefly, the sponges are intended to 
be competitive inhibitors of endogenous miRNAs that are expressed from strong 
promoters and driven by RNA polymerase II [35].  A construct was cloned bearing 
multiple bulged miR-483-3p binding sites to into the 3’ UTR of the GFP gene in 
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the pLentilox 3.7 lentiviral vector.  The plasmid was packaged into viral particles 
to overcome the inherent difficulty of transfecting the H295 cell line and a viral 
transduction approach was used to attain strong levels of GFP expression.  
While the cloning and transduction of the miR-483-3p sponge was successful, we 
were unable to conclusively determine if the sponge was functional.  This was 
due in part to the lack of data regarding validated miR-483-3p targets, against 
which we could compare the effects of the sponge.  Instead, we chose to assess 
proliferation because IGF2 is a known mitogen in ACC.  We hypothesized that 
the co-expression of miR-483-3p may have a similar function, and therefore a 
functional miR-483-3p sponge might have a negative effect on proliferation of 
cells expressing this miRNA.  However, pilot experiments that analyzed the 
proliferation of NCI-H295 cells transduced with the miR-483-3p sponge construct 
were inconclusive.  Growth curves of H295 cells transduced with the miR-483-3p 
sponge relative to control plasmid were erratic and inconsistent over the time 
course of both a short term (4 days) and long term (6 days) experiment (Figure 
2.9).  The total number of viable cells at each experimental endpoint, however, 
were consistently lower in H295 cells transduced with the miR-483-3p sponge.  
The results from these pilot experiments did not definitively support the 
hypothesized effects on proliferation stemming from miR-483-3p inhibition, 
indicating the sponge may not have functioned effectively and may require 
further optimization, or that miR-483-3p does not play a significant role in 
promoting cellular proliferation as hypothesized.  
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 We also determined a list of predicted miR-483-3p mRNA targets that, 
according to the array data cited previously, were down-regulated in IGF2/
miR-483-3p expressing primary human ACC samples.  This list consisted of 
BMPR2, EGR1, H3F3B, IGF1, MLLT6, QKI, TMOD1, USP46, and VAMP2.  We 
focused on IGF1 and EGR1 (Early growth response protein 1), as IGF1 is a 
known adrenal mitogen, and EGR1 has been demonstrated to possess tumor 
suppressor properties.  Quantitative real-time PCR for IGF1 and EGR1 
transcripts in H295 cells transduced with the miR-483-3p sponge demonstrated a 
slight increase of EGR1 expression relative to H295 cells transduced with control 
plasmid (Figure 2.10).  In contrast, H295 cells transduced with the miR-483-3p 
sponge responded inconsistently with regard to IGF1 expression.  Half of the 
replicates analyzed demonstrated a further decrease in IGF1 transcript, contrary 
to the expected result, and a only single replicate showed a marked increase in 
IGF1 expression.  Together these data suggest the miR-483-3p sponge had a 
modest effect on de-repressing EGR1 transcript levels in transduced H295 cells.  
However, the data on IGF1 transcript levels in cells transduced with the 
miR-483-3p sponge were inconclusive, and would require additional 
investigation.     
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Discussion
 This chapter describes the efforts to investigate the correlation between 
IGF2 expression in primary human ACCs and the expression of miR-483-3p, a 
miRNA that is located within the second intron IGF2.  We also attempted to 
generate potential molecular tools that could aid in the study of miR-483-3p and 
its functional role in the human ACC cell line H295R.  Our data, while preliminary 
in nature, supported the correlation between IGF2 and the co-expression of 
miR-483-3p with its host gene.  We also performed several experiments to 
analyze potential physiological effects of miR-483-3p inhibition in vitro by testing 
a miRNA “sponge” designed to specifically respond to miR-483-3p.  
 The experiments designed to assess proliferation in H295 cells transduced 
with the sponge yielded inconclusive results, which may be due to several 
factors.  One likely explanation may be due to poor efficacy of the sponge 
designed in this study.  We designed the sponge with three potential miR-483-3p 
binding sequences that consisted a perfect seed region match and non-
complementary bulge in the central region of the miRNA-target sequence.  It is 
possible that three binding sites were not sufficient to effectively inhibit 
endogenous miR-483-3p activity in H295 cells, which express very high levels of 
this miRNA.  Additionally, the binding sequences in the sponge were separated 
by only four nucleotides, which may have resulted in steric hindrance of miRISC 
bound miR-483-3p, preventing access to all three binding sites.  Another 
explanation is that miR-483-3p does not significantly affect proliferation, and that 
its host gene, IGF2, primarily mediates the proliferative capacity of H295 cells.  
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Indeed, IGF2 has been specifically implicated as an autocrine regulator of 
proliferation in the NCI-H295R human ACC cell line [37].  Finally, there may be 
additional uncharacterized molecular pathways independent of miR-483-3p or 
IGF2 that promote proliferation in the H295 cell line.  
 We also compared a list of predicted miR-483-3p targets using the 
TargetScan algorithm (www.targetscan.org) with down-regulated gene transcripts  
found in primary human ACCs that express high IGF2 and miR-483-3p.  Of the 
nine predicted targets to be down-regulated in human ACCs, we were interested 
to discover that IGF1 and EGR1 were among those target genes.  IGF1 is a 
known adrenal mitogen, and in humans, is co-expressed in the adult adrenal in 
conjunction with IGF2.  In ACC, IGF2 is up-regulated, and IGF1 expression often 
decreases, recapitulating the embryonic adrenal in which IGF2 is the 
predominant growth factor [12].  The prediction of IGF1 as a target of miR-483-3p 
raises the possibility of a regulatory mechanism in which IGF1 expression is 
repressed indirectly by IGF2.  This could be a potential mechanism that 
maintains the balance between IGF1 and IGF2 expression in the adult adrenal.  
 Finally, EGR1 is an interesting predicted miR-483-3p target because of its 
tumor suppressor function that has been reported in the literature [38,39].  EGR1 
is a zinc-finger transcription factor that has been demonstrated to induce the 
expression of p53, PTEN, and c-Jun, and is down-regulated in a variety of 
cancers including glioma, lymphoma, and carcinoma of the breast [40-44].  In 
contrast, EGR1 is often up-regulated in prostate cancer [45,46], and intriguingly, 
has been demonstrated to induce the expression of IGF1R [47], the key IGF2 
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receptor in ACC.  However, given that EGR1 is down-regulated in the primary 
human ACCs analyzed in our array, this suggests that EGR1 may act in the role 
as a tumor suppressor in the context of ACC.  In this case it would be reasonable 
to hypothesize that as a predicted target of miR-483-3p, EGR1 expression is 
inhibited in ACCs that express high levels of IGF2, contributing to the 
tumorigenesis of ACC.        
 More recent studies into the potential targets of miR-483-3p in the context 
of cancers have reported that miR-483-3p does indeed have a pro-oncogenic 
function in human neoplasms including Wilm’s Tumor, colon, breast, and liver 
tumors.  These same reports have also identified a potential role for miR-483-3p 
as an oncogene that inhibits apoptosis and promotes proliferation in the human 
ACC cell line H295R by repressing the pro-apoptotic protein, p53 up-regulated 
modulator of apoptosis (PUMA) [48,49].
 Our data appeared to show robust correlation between IGF2 and 
miR-483-3p expression, suggesting the expression of the latter is dependent on 
the former.  In addition, it has been recently demonstrated that expression of 
miR-483 can be induced by the Wnt/β-catenin signaling independent of IGF2, 
adding an additional layer of complexity to the regulation of miR-483 expression 
[50].  Recent studies have shown that other intronic miRNAs, most notably 
miR-21, can be regulated independently of their host genes in a similar manner.  
In the case of miR-21, it has been shown that TGF-β signaling can promote the 
processing and expression of miR-21 through a positive interaction between 
Smads, the downstream effector proteins of TGF-β signaling, and Drosha, the 
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RNase III enzyme responsible for processing primary miRNA transcripts into 
precursor transcripts ready for nuclear export [51,52].  Considering that both the 
Wnt/β-catenin and TGF-β signaling pathways are implicated in the process of 
tumor formation, the discovery that these signaling pathways can directly 
promote the expression of miRNAs involved in oncogenesis such as miR-483-3p 
and miR-21 means consideration must be given to identifying the targets of these 
miRNAs implicated in cancer.  
 The potential involvement of β-catenin in regulating the miR-483 locus is 
intriguing, as abnormal nuclear localization of β-catenin, indicative of active 
signaling, is characteristically associated with poorer prognosis and outcome in 
human ACC cases [53,54].  It has further been reported that Wnt/β-catenin 
targets are over-expressed in cases of human ACC [55].  Although IGF2 or β-
catenin dysregulation is most often associated with poor outcome and prognosis 
in ACC, there are few studies that evaluate the simultaneous effects of both IGF2 
and β-catenin dysregulation on ACC development.  Igf2 over-expression alone in 
mouse models fails to induce ACC, although these mice exhibit non-malignant 
adrenal defects consistent with the Beckwith-Wiedemann syndrome seen in 
humans [56,57].  Mice engineered to constitutively express β-catenin have been 
reported to develop adrenal hyperplasia, dysplasia, increased adrenal 
vascularization, and ultimately neoplasia in aging mice [58].  This model of 
progressive adrenal pathology is similar to the multi-hit progression seen in 
colorectal cancer, suggesting that single genetic defects alone may not be 
enough to promote the development of ACC, and that other genetic hits are 
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necessary for carcinogenesis.  A long term study conducted in our lab to 
investigate the potential synergistic effects of simultaneous dysregulation of Igf2 
active β-catenin in the mouse adrenal gland is currently in press [59] and 
provides evidence supporting the hypothesis that multiple genetic hits may be 
required for the tumorigenesis of ACC.  
 We did not assess the specific human ACC samples used in this study for 
dysregulated β-catenin expression; nor did we assess ACC samples with high β-
catenin expression for miR-483-3p.  As such, we cannot comment as to whether 
β-catenin could be in part responsible for the high levels of miR-483-3p that are 
seen these samples.  Given that miR-483-3p has oncogenic properties by 
repressing PUMA, leading to decreased apoptosis, it is possible that the IGF2 
and β-catenin dysregulation seen in human ACCs converge to a common 
pathway that involves miR-483-3p and its repression of PUMA and other genes.  
Further studies would need to be performed to investigate this possibility in both 
ACCs and other cancers characterized by increased β-catenin expression.     
 The field of miRNAs and the understanding of their involvement in 
development and disease has expanded tremendously since we initially began 
these studies.  Although we were successful in generating several molecular 
tools that might be useful in studying the effects of miR-483-3p in vitro, the 
abundance, quality, and cost effectiveness of commercially available tools that 
have rapidly come on the market has made working with miRNAs significantly 
faster.  With the increased availability of commercially produced molecular tools 
designed to study the function of individual miRNAs, it has become much easier 
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for researchers to perturb miRNAs of interest in cell culture systems, or even 
whole animal models.  To illustrate this, while we were investigating the 
relationship between IGF2 and miR-483-3p in the NCI-H295 cell lines, the 
previously cited reports correlating miR-483-3p with poorer disease prognosis 
and establishing PUMA as a target were published by an independent laboratory 
[48].  As a result, we therefore elected to expand our studies by addressing the 
role of miRNAs in adrenal development by utilizing a genetic knockout approach 
that will be described in Chapter 3.  However, there is still much work that can be 
pursued regarding the interplay between miR-483-3p, IGF2, and ACC.  Future 
studies involving IGF2 and miR-483-3p would benefit greatly from the recent 










Figure 2.1 Tissue Classification & IGF2 Locus Heatmap of Human Adrenal 
Samples.
A heat map showing the histological classification and expression levels of the 
IGF2 locus genes at 11p15.5 in normal human adrenals, adrenal adenomas, and 
adrenal carcinomas.  
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Figure 2.2 Relative fold expression of IGF2 and miR-483-3p in human 
adrenal tissue samples and cell lines.
Quantitative real-time PCR for both IGF2 (A) and miR-483-3p (B) transcript 
expression in human adrenal (normal, high IGF2, low IGF2) samples and human 
cell lines.  Fold expression is relative to normal human adrenals (for ACC 
samples) and the RL251 cell line (for human cell lines).  


































































































































































Figure 2.3 Correlation between IGF2 and miR-483-3p expression in human 
adrenal tissue and cell lines.
Linear regression analysis performed on real time PCR ΔCt values for IGF2 and 
miR-483-3p.  Each square represents one sample.  (A) Correlation between 
IGF2 and miR-483-3p for human adrenal tissue samples (p<.05; R2=.8021).  (B) 
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Figure 2.4 miR-483-3p over-expression vector construction.
Schematic showing the strategy used to develop the miR-483 expression vector.  
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Figure 2.5 Quantitative real time PCR on cell lines transfected with 
miR-483-3p expression vector.
miR-483-3p expression in SW13 cells that do not express endogenous 
miR-483-3p.  Fold changes relative to SW13 cells transfected with control 
pMSCVpuro vector (SW13 OEV).  H295R cells known to express endogenous 
miR-483-3p used as positive controls (295R1 & 295R2).
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Figure 2.6 miR-483-3p luciferase reporter construction.
Schematic illustrating the strategy used to generate miR-483-3p luciferase 
sensor using the pGL3-Control plasmid.
91
pGL3 miR-483 Reporter Assay in SW13 Cells















































Figure 2.7 Luciferase activity in SW13 cells transfected with miR-483-3p 
expression vector.
SW13 cells were transfected with either empty control pMSCVpuro (SW13 -EV) 
or pMSCVpuro-miR483 expression vector (SW13 +EV).  The miR-483-3p 
luciferase reporter plasmid (Reporter), or control pGL3-Control plasmid (Control) 








































Figure 2.8 Luciferase assays on H295R cells transfected with the 
miR-483-3p sensor.
Effect of endogenous miR-483-3p expression on the luciferase reporter construct 
in H295A and H295R cells.  Cells transfected with the miR-483-3p luciferase 
reporter (Reporter) show significantly less (*p<.05) luciferase activity compared 
to cells transfected with control pGL3-Control luciferase plasmid (Control). 
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Figure 2.9 Growth curves of H295A and H295R cells transduced with the 
miR-483-3p sponge.
Growth curves of H295A and H295R cells transduced with either control plasmid 
or miR-483-3p sponge.  Cells were plated at a density of 5 x 105 cells per well 
and followed for up to 4 days (A) or 6 days (B).  Cells were harvested on days 
denoted by data points on the line graph and counted.
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Figure 2.10 IGF1 and EGR1 transcript levels in H295 cells transduced with 
the miR-483-3p sponge.
Expression of IGF1 and EGR1 in H295 cells transduced with the miR-483-3p.  
Each column represents an independent replicate, and shows expression relative 
to a corresponding control (H295 cells transduced with control plasmid).  The 
dotted horizontal line at 1 denotes the baseline expression in control samples.  
miR-483-3p sponge induced a modest increase in EGR1 transcript levels in 3/4 
replicates analyzed.  IGF1 response to the miR-483-3p sponge was inconclusive. 
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Deficient Mouse Adrenals
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Introduction
 The adrenal glands are bilateral structures located superior to the kidneys.  
They are critical components of the hypothalamic-pituitary-adrenal (HPA) axis, 
and have important functions in maintaining electrolyte and metabolic 
homeostasis, as well as regulating the stress response.  The adrenal gland is 
comprised of two embryologically and functionally distinct cell types:  The adrenal 
cortex, which is derived from the coelomic epithelia and intermediate mesoderm 
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known as the urogenital ridge; and the adrenal medulla, which is comprised of 
neuroendocrine cells derived from the neural crest [1,2].  
 The adrenal cortex initially forms as a coalescence of cells known as the 
adrenogonadal priomordium (AGP) at approximately embryonic day 9 (E9.0) [3].  
This bi-potential mass of cells then further develops into two distinct cell 
populations that eventually comprise the steroid secreting cells of the gonad and 
adrenal cortex.  It is at this time that steroidogenic factor 1 (Sf1), a key regulator 
of steroidogenic enzymes in the adrenal cortex and steroid secreting cells of the 
gonads, begins to be expressed in the AGP [4].  By E12.0, a distinct adrenal 
primordium consisting of fetal adrenocortical cells forms.  At approximately the 
same time, medullary precursor cells from the neural crest begin migrating into 
and populating the fetal adrenal cortex [1].  Shortly thereafter, mesenchymal cells 
from the surrounding stroma coalesce to form the adrenal capsule, which is 
where a population of adrenocortical stem/progenitor cells is believed to reside 
[5].  As encapsulation progresses, the fetal adrenal cortex is replaced by the 
adult or definitive cortex, which has been shown to have regenerative properties 
that presumably facilitate the continued turnover and replenishment of 
adrenocortical cells throughout the life of the organism [6].  
 The necessity of Sf1 in adrenal development is absolute for the 
development and maintenance of the adrenal gland.  Sf1-null mice die shortly 
after birth likely due to adrenocortical insufficiency, and also completely lack both 
adrenal glands and gonads [7].  However, there are numerous additional 
regulatory factors and signaling pathways that have also been implicated in the 
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specification, development and maintenance of the adrenal cortex.  These 
include dosage-sensitive sex reversal, adrenal hypoplasia congenita critical 
region on the X chromosome, gene1 (Dax1); pre B-cell leukemia homeobox 1 
(Pbx1); Wnt/β-catenin signaling; sonic hedghog signaling (Shh); Cdkn1c (p57kip2) 
which is implicated in the intrauterine growth restriction, metaphyseal dysplasia, 
adrenal hypoplasia congenita, and genital anomaly syndrome (IMAGe); and most 
recently, Pod1 (Tcf21) [8-14].  The interplay between these regulatory and 
signaling pathways that occurs in the developing adrenal gland is highly complex 
and intricate, and the exact roles of each of them has yet to be fully understood. 
 Recently, the role of post-transcriptional regulation in the form of miRNAs 
has been investigated in development and physiology, including in the 
developing adrenal.  miRNAs are short, endogenous, non-coding RNA transcripts  
first described in C. elegans [15].  Initially thought to be an idiosyncrasy found in 
nematodes, they are present in most eukaryotic cells, consistent with a critical 
evolutionary role for these transient and previously dismissed RNA transcripts.  
The canonical function of miRNAs is that of post-transcriptional regulation of 
gene expression, and this is accomplished by binding to target gene mRNAs 
through partially complementary sequences in the 3’ untranslated region (UTR).  
In conjunction with a protein complex known as the miRNA Induced Silencing 
Complex (miRISC), miRNAs bind to target mRNA transcripts to inhibit translation 
by destabilizing the target transcript and facilitating degradation, or inhibiting the 
translational machinery [16,17].  These mechanisms have the effect of 
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subsequently inhibiting the protein expression of specific genes within a cell, fine 
tuning the gene expression within a cell to maintain homeostasis.   
 Since the groundbreaking observation in 1993 by Lee et. al., the field of 
miRNAs has rapidly expanded, and along with it our understanding of their 
functions in development, physiology, and disease processes.  miRNAs appear 
to be crucial in development, as mice deficient in Dicer, the RNAse III enzyme 
required for miRNA maturation, do not survive beyond embryonic day 8.5 (E8.5), 
due to arrested embryonic development beginning at E7.5 [18].  Subsequent 
studies involving tissue-specific Dicer knockout mouse models show that Dicer is 
required for normal organogenesis and tissue maintenance in a variety of organs 
including the heart, lung, skin, muscle, and gonads [19-25].  Additionally, Dicer 
has shown to be required for the maintenance of embryonic and tissue stem cells 
[26,27], suggesting a role for Dicer and miRNA expression in regulating cellular 
differentiation.    
 In this study we utilized a genetic approach to ablate Dicer in the 
steroidogenic cells of the adrenal cortex.  The resulting adrenocortical Dicer KO 
mice underwent normal adrenal development through embryonic day E14.5.  
However, the adrenal cortex underwent rapid degeneration beginning at E16.5.  
By E18.5, the adrenal cortex had completely failed to the point of there being a 
near complete absence of cortical tissue.  MicroRNA and mRNA array analysis 
showed that Dicer KO adrenals had distinct expression profiles relative to wild 
type controls, including the up-regulation of Nr6a1, Igdcc3, and Acvr1c; the data 
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also revealed the concurrent down-regulation of miRNAs predicted to target 




 Experiments involving live animals were performed in accordance with 
current and institutionally approved protocols and animal care guidelines.  Sf1-
Crehigh and Sf1-Crelow  mice were obtained and described previously [9,28].  Mice 
carrying the floxed Dicer allele (Dicer1tm1Bdh/J) were purchased from The Jackson 
Laboratory (Bar Harbor, ME).  
 To obtain Sf1-Cre/Dicerlox/lox mice, Sf1-Cre/Dicer+/lox and Dicerlox/lox mice 
were mated together.  Females from each mating pair were monitored for 
seminal plugs, and the morning of detection was designated as E0.5.  Pregnant 
females were sacrificed and harvested at designated timepoints, and embryos 
were staged using Theiler staging criteria as described by the e-mouse Atlas 
Project (www.emouseatlas.org).  Genotyping for the Sf1-Cre and Dicerlox allele 
was performed on tail sections from both embryos and adult mice as previously 
described [28,29].  For long term observations of Sf1-Crelow/Dicerlox/lox mice, 
control and knockout offspring were sacrificed at 6, 13, 18, 30, and 50 weeks of 
age.  Adrenals were bilaterally excised, cleaned of excess fatty tissue, and 
weighed.  Adrenal weights were normalized to the body weight of the animal from 
which they were isolated.  Left adrenals were collected for histologic processing, 
and the contralateral glands were utilized for RNA isolation.  
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Dexamethasone suppression/ACTH stimulation test and plasma 
corticosterone RIA
 50 week old Sf1-Crelow/Dicerlox/lox (n=7) and 50 week old control mice (n=5) 
were subject to ACTH stimulation and tail vein blood collection prior to sacrifice 
as described previously [30].  Animals were intra-peritoneally injected (IP 
injected) with 5mg/kg body weight dexamethasone (Sigma-Aldrich, St. Louis, 
MO) at 1800 hours the night before and at 0800 hours the day of the assay.  At 
1000 hours, 1mg/kg body weight of ACTH [ACTH (1-24); Bachem, Torrance, CA] 
was IP injected.  Blood was collected by venous tail vein puncture at 0, 15, 30, 
and 60 minutes post-ACTH injection. 
 Serum corticosterone levels in 50 week old knockout and control animals 
were measured by radioimmunoassay (RIA) using a 125I RIA kit (MP Biomedicals, 
Solon, OH) using the manufacturer’s instructions.  Samples were run in triplicate 
and quantified using a Gammer Counter.  All measurements were within the 
standard curve of the assay.   
Adrenal histology, immunohistochemistry, and immunofluorescence
 Tissues were fixed between 2-4 hours in 4% paraformaldehyde and then 
dehydrated in a series of graded ethanol solutions before paraffin embedding.  
7µm sections were cut and placed on microscope slides for further manipulation.
 Hematoxylin and eosin staining was performed by deparaffinizing tissue 
sections in xylene, then rehydrated in graded ethanol solutions of decreasing 
concentration.  Slides were dipped in hematoxylin for 3 seconds, then 
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immediately transferred to deionized water and rinsed with running deionized 
water for several minutes.  Slides were counterstained by a 3 second immersion 
in eosin, then rinsed and dehydrated in a series of ethanol and xylene baths, and 
finally mounted with Permount (ThermoFisher, Waltham, MA).
 Immunohistochemistry was performed by processing tissue sections as 
described above.  Following rehydration, slides were subjected to antigen 
retrieval by boiling in 10mM sodium citrate (ph 6) for 20 minutes.  After cooling, 
slides were washed once in deionized water followed by 2 washes in Tris-
buffered saline/0.1% Tween-20 (TBST, ph 7.5).  Antibody staining was performed 
with VECTASTAIN ABC kits (Vector Laboratories, Burlingame, CA) according to 
the manufacturer’s protocol.  Tissue sections were blocked in antibody diluent 
solution for 1 hour at room temperature, then incubated overnight at 4°C with 
anti-p21 (1:100, BD Pharmingen, San Diego, CA), anti-cleaved-caspase 3 
(1:100, Cell Signaling, Danvers, MA), anti-Sf1 (1:1000, custom antibody), and 
anti-tyrosine hydroxylase (1:500, Pel-Freez Biologicals, Roger, AR).  The 
following day, sections were washed 3 times in TBST, then 2 times in deionized 
water.  Incubation with biotinylated secondary antibodies was performed for 1 
hour at room temperature, and subsequent staining via 3,3’-Diaminobenzidine 
(DAB) was performed according to the manufacturer’s instructions.  DAB stained 
tissue sections were then counterstained with either diluted (1:10 deionized 
water) eosin or hematoxylin.  Slides were finally mounted using Permount 
coverslip mounting medium, allowed to cure overnight at room temperature, and 
imaged using light microscopy.
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 Fluorescent labeled tissue sections were processed and cut as described 
above.  Antigen retrieval was performed by boiling slides in 10mM citric acid (pH 
6) for 30 minutes.  After cooling to room temperature, tissue sections were 
blocked with PBS/2% non-fat dry milk/2% normal goat serum for 1 hour at room 
temperature.  Sections were then incubated overnight at 4°C with anti-Sf1 
(1:1000, custom antibody), anti-tyrosine hydroxylase (1:300, Millipore, Billerica, 
MA), and anti-PCNA (1:500, Santa Cruz, Santa Cruz, CA).  The following 
morning, slides were washed 3 times in PBS, then 2 times in deionized water 
before incubation with DylightTM 488 conjugated goat anti-rabbit or DylightTM 549 
conjugated goat anti-mouse (1:1000, Jackson ImmunoResearch Laboratories, 
West Grove, PA) for 1 hour in the dark at room temperature.  All antibodies were 
diluted in PBS containing 0.2% non-fat dry milk and 0.2% normal goat serum.  
Slides were washed again 3 times in PBS, followed by 2 washes in deionized 
water.  The fluorescently labeled tissue sections were counterstained with 4',6-
diamidino-2-phenylindole (DAPI, 1:1000, Sigma-Aldrich, St. Louis, MO).  
Coverslip mounting was performed using Tris-buffered Fluorogel (Electron 
Microscopy Sciences, Hatfield, PA), cured for 24 hours in the dark at room 
temperature, then visualized by fluorescent microscopy.
Quantitative Real-time PCR
Total RNA was isolated from the adrenals of control and Dicer KO animals were 
processed using either TRIzol reagent or the RNAqueous Micro kit (Life 
Technologies, Carlsbad, CA) to isolate total RNA.  Up to 1µg of RNA was reverse 
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transcribed using the iScript system (Bio-Rad Laboratories, Hercules, CA) to 
generate cDNA.  1µL of the resulting cDNA was amplified with appropriate 
primers using Power SYBR Green PCR Master Mix and analyzed on an ABI 
7300 Real Time PCR System (Applied Biosystems, Carlsbad, CA).  Data 
analysis was performed using the 2-∆∆C(T) method [31].  Gene expression was 
normalized to mouse β-Actin. Primers for each amplified gene are as follows:  
β-Actin (Actb), Fwd 5’-CTAAGGCCAACCGTGAAAAG and 
Rev 5’-ACCAGAGGCATACAGGGACA; 
Sf1 (Nr5a1), Fwd 5’-TCCAGTGTCCACCCTTATCC and 
Rev 5’-CGTCGTACGAATAGTCCATGC; 
11β-hydroxysteroid dehydrogenase (Cyp11b1), Fwd 5’-
GCCATCCAGGCTAACTCAAT and Rev 5’-CATTACCAAGGGGGTTGATG; 
11β-aldosterone synthase (Cyp11b2), Fwd 5’-GCACCAGGTGGAGAGTATGC 
and Rev 5’-CCATTCTGGCCCATTTAGC; 
ACTH receptor (Mc2r), Fwd 5’-TGGAAAAGTTCTCAGCACCAC and 
Rev 5’-TCTTTGTGTGGAAGGATCTGG; 
steroidogenic acute regulatory protein (Star),
 Fwd 5’-TTGGGCATACTCAACAACCA and Rev 5’-ACTTCGTCCCCGTTCTCC; 
cholesterol side chain cleavage enzyme (Scc), Fwd 5’-
AAGTATGGCCCCATTTACAGG, and Rev 5’-TGGGGTCCACGATGTAAACT; 




 Timed matings were established to generate Sf1-Crehigh/Dicerlox/lox 
knockout embryos.  At E15.5 and E16.5, pregnant females were sacrificed, and 
embryos were collected and staged according to the criteria referenced above.  
Adrenals from each embryo were micro-dissected and stored separately in 
RNAlater solution (Invitrogen, Carlsbad, CA) until genotyping confirmed Dicer KO 
status.  The adrenals from control and Dicer KO littermates were pooled for 4 
separate litters, resulting in a total of 4 control and 4 Dicer KO biological 
replicates at both E15.5 and E16.5 timepoints.  Total RNA was isolated using the 
RNAqueous Micro kit (Invitrogen, Carlsbad, CA) in accordance with the 
manufacturer’s protocol to preserve small RNA recovery.  Isolated RNA was 
quantified on a Nanodrop 2000c spectrophotometer (Thermo Scientific, 
Wilmington, DE), and submitted to the University of Michigan Microarray Core 
Facility where samples were quality checked and finally analyzed with both 
Affymetrix Mouse 430 2.0 gene expression arrays and ABI miRNA OpenArrays.     
Statistical Analysis
 Microarray data were normalized using the robust multiarray average 
(RMA) algorithm [32].  MicroRNA data were normalized to the U6 rRNA value on 
the corresponding subpanel of the Openarray.  For both types of arrays, 
differential gene expression between conditions was determined using the limma 
package by applying linear modeling followed by the empirical Bayes method to 
compute significance [33].  The resulting p-values were adjusted for multiple 
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testing by the Benjamini-Hochbberg method [34]. Genes with an absolute log2 
fold change greater than or equal to 1.5 with an adjusted p-value of less than .05 
were considered differentially expressed and statistically significant.  For the 
DAVID analysis, each collection of differentially expressed genes was evaluated 
for gene-enrichment by submitting the Entrez Gene identifiers to DAVID and 
running the default analysis. Functional classifications with a false discovery rate 
(FDR) ≤ 5% were considered significant [35].
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Results
Sf1-Crelow/Dicerlox/lox mice survive up to 50 weeks and have no appreciable 
deficits in adrenal morphology or steroidogenesis
 We generated knockout (KO) mice that lack Dicer expression in the 
adrenal cortex by breeding mice carrying the Sf1 promoter-driven Cre transgene 
and one copy of the floxed Dicer allele (Sf1-Cre/Dicerlox/lox) with mice carrying 
homozygous floxed Dicer alleles (Dicerlox/lox).  The contrasting effects of the low 
and high Sf1-Cre transgenes have been described [9].  Briefly, the single-copy 
Sf1-Crelow transgene (low driver) results in partial penetrance of Cre recombinase 
expression and a milder phenotype compared with the Sf1-Crehigh transgene 
(high driver) that contains five copies and results in full phenotypic penetrance.  
Because of the rapid and drastic nature of the phenotypes seen in other tissue 
specific Dicer knockout models, we chose to initially study Sf1-Crelow/Dicerlox/lox 
(low driver Dicer KO) offspring in our study to determine whether a stochastic, 
partial deletion of Dicer could provide insight into its role in the long- term 
maintenance of the adrenal cortex.  
 Sf1-Crelow/Dicerlox/lox mice were housed separately according to sex and 
followed for 6, 18, 30, and 50 weeks of age.  Small cohorts of at least n=2 were 
sacrificed at each time point up 30 weeks, and the adrenals from these animals 
were analyzed.  We were unable to detect any appreciable physiologic or 
histologic phenotype at the earlier timepoints (data not shown).  We then 
concentrated our analysis on the 50 week Sf1-Crelow/Dicerlox/lox mice by testing a 
larger cohort (n ≥ 5) for functional and gene expression perturbations.  However, 
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we were unable to observe any appreciable differences in phenotype between 50 
week old control versus low driver Dicer KO adrenals.  Figure 3.1 illustrates 
representative hematoxylin and eosin stained sections from control and low 
driver Dicer KO adrenals at the 50 week timepoint, with additional to 
immunohistochemistry for the adrenocortical marker Sf1, and the medullary 
marker tyrosine hydroxylase.  No appreciable structural changes in the adrenal 
such as capsular thickening or changes in cortical mass were observed.  
Likewise, there were no discernible differences in Sf1 or tyrosine hydroxylase 
staining as assessed by immunohistochemistry.  Comparison of normalized 
adrenal weights between 50 week old control and low driver Dicer KO animals 
showed a slight trend in which the KO adrenals were on average slightly smaller 
in size than control adrenals, but this difference was not statistically significant.  
(Figure 3.2A)  Prior to sacrifice, 50 week old control and low driver Dicer KO 
animals were subjected to an ACTH stimulation test to compare maximum 
steroidogenic output.  This has been described in previous studies [30] as a 
method to measure adrenal function in vivo.  We were unable to detect a 
significant difference between 50 week old control and low driver Dicer KO mice 
in ACTH-stimulated corticosterone output at 0, 15, 30, and 60 minutes post 
injection (Figure 3.2B).  Therefore, 50 week old low driver Dicer KO adrenals 
maintained normal steroidogenic function.  Finally, 50 week old control and low 
driver Dicer KO adrenals were compared by quantitative real-time PCR to 
determine whether any differences were detectable at the transcriptional level.  
Except for a decrease in Dicer transcript levels in 50 week old Dicer KO 
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adrenals, the relative expression of steroidogenic enzyme encoding transcripts 
remained constant between control and low driver Dicer KO adrenals (Figure 
3.2C).  In summary, no significant morphological or functional deficits were 
detected in the adrenals of 50 week old low driver Dicer KO mice compared to 
control animals.  These results indicate that low driver Dicer KO adrenals can 
compensate for the loss of Dicer in a subpopulation of cortical cells, or perhaps 
Dicer function is not required in these cells.  To further explore these possibilities, 
we then performed experiments aimed at determining the effects of Dicer 
deletion in all Sf1 expressing cortical cells by examining the adrenal glands in 
Sf1-Crehigh transgenic mice.    
High driver (Sf1-Crehigh/Dicerlox/lox) Dicer KO mice die shortly after birth
 While we did not observe a significant phenotype in the adrenal glands of 
low driver Dicer KO animals as old as 50 weeks, the more robust expression 
pattern of Cre recombinase in the high driver Dicer KO animals resulted in a 
marked adrenal defect that proved to be lethal.  Based on our breeding strategy, 
embryonic (E14.5-E18.5) and post-weaning (21 days post-parturition) offspring 
were expected to demonstrate Mendelian genotypic ratios in which 25% of 
progeny should have been positive for the Sf1-Crehigh/Dicerlox/lox genotype.  
However, high driver Dicer KO animals were not observed at weaning, and the 
expected Mendelian ratios for the Sf1-Crehigh/Dicerlox/lox genotype were seen only 
at the embryonic stages. Mortality among Sf1-Crehigh/Dicerlox/lox animals occurred 
1-2 days post-parturition, and no Sf1-Crehigh/Dicerlox/lox offspring survived beyond 
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this timepoint.  Therefore, Sf1-Crehigh/Dicerlox/lox offspring invariably died shortly 
after birth.  This perninatal lethality in high driver Dicer KO animals is also 
supported by a previous report [36].  
High driver (Sf1-Crehigh/Dicerlox/lox) Dicer KO mice exhibit adrenal failure late 
in embryonic development
 Due to the perinatal lethality of the high driver Dicer KO model, we 
performed detailed analyses of adrenal histology at various embryonic time 
points in these animals.  E14.5 is the earliest time point in development where 
the adrenal has fully separated from adrenal-gonadal primordium, and medullary 
precursor cells have migrated from the neural crest into the adrenal.  We were 
unable to detect significant histological changes at E14.5 (Figure 3.3B) between 
control and high driver Dicer KO adrenal glands.  This implies that the fetal 
adrenal cortex in high driver Dicer KO animals undergoes normal specification 
and formation, and that Dicer loss in Sf1 positive cells is not initially detrimental 
to early adrenal development.  In contrast, Sf1-null animals demonstrate marked 
developmental defects in the gonad and adrenal as early as E12.5 [7], illustrating 
the global necessity of Sf1 for proper adrenogonadal development.  Adrenals 
from E16.5 high driver Dicer KO animals were still present compared with control 
adrenals, but cortical thickness was decreased in the sections that were 
analyzed.  However, adrenals from KO animals still exhibited distinct cortical and 
medullary demarcations.  The most significant phenotype in high driver Dicer KO 
animals occurred at E18.5.  As shown in Figure 3.3B, adrenals from high driver 
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Dicer KO animals at this time point demonstrated a nearly complete absence of 
the cortex.  Additionally, the overall size of the adrenal in Dicer KO animals was 
markedly smaller than control counterparts (Figure 3.3A).  Interestingly, the 
adrenal medulla, which is derived from a separate cell lineage than the cortex, 
persisted in the high driver Dicer KO adrenals.  Finally, an unidentified population 
of small, basophilic cells was observed between the medullary cells and the 
adrenal capsule.    
 To further characterize the phenotype seen in high driver Dicer KO 
adrenals, immunofluorescent antibody co-staining was performed on sections 
from control and Dicer KO adrenal sections as described in Materials and 
Methods.  At the earlier time point of E14.5, both the adrenal cortex and medulla 
appear to be intact in both control and high driver Dicer KO adrenals, as 
evidenced by anti-Sf1 and anti-tyrosine hydroxylase staining (Figure 3.3C).  
However, as development progressed, cortical mass, as defined by Sf1-positive 
cells, began to decrease at E16.5.  By E18.5, Dicer KO animals had very few 
residual Sf1 expressing cortical cells remaining in the adrenal gland.  Again, 
tyrosine hydroxylase expressing medullary cells persisted at E18.5 in Dicer KO 
adrenals, despite the severe cortical failure that was observed.  
 In summary, high driver Dicer KO adrenals underwent normal early 
development, with adrenal-gonadal separation and formation of the fetal adrenal 
cortex, followed by infiltration of the developing cortex by neural crest derived 
medullary precursor cells by E14.5.  However, beginning at E16.5, the Dicer KO 
adrenals exhibited a gradual loss of Sf1 positive cortical cells that accelerated 
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rapidly and led to the complete absence of the cortex by E18.5.  This marked 
phenotype is incompatible with life, as evidenced by the perinatal lethality 
observed in high driver Dicer KO animals which do not survive beyond one or 
two days following live birth.  
High Driver Dicer KO Adrenals Exhibit Increased dsDNA Damage and 
Apoptosis
 We further investigated the adrenocortical destruction in high driver Dicer 
KO animals by examining differences in cortical proliferation or apoptosis versus 
control mice.  In the adrenal gland, proliferating cortical cells are most abundant 
in the outer peripheral region of the cortex [37].  Anti-PCNA stained adrenal 
sections from control and Dicer KO animals were co-stained with anti-Sf1 to 
localize proliferating cells.  Our results demonstrated that Sf1 expressing, 
proliferating cells localized to the sub-capsular cortical region were were present 
in the periphery of high Driver Dicer KO adrenals, suggesting that loss of Dicer in 
cortical cells did not significantly affect proliferation (Figure 3.4A). 
 We then addressed the question of whether Dicer loss in the adrenal 
cortex induced cell cycle arrest and apoptosis.  Immunohistochemistry for 
Cdkn1a (p21) and cleaved-Caspase 3 indicated significant increases in the 
expression of these proteins in high driver Dicer KO adrenals (Figure 3.4B and 
Figure 3.4C).  The expression pattern of p21 and cleaved-Caspase 3 in Dicer KO 
adrenals was limited primarily to the cortex, and could be detected as early as 
E14.5.  This was surprising as we were not able to otherwise appreciate an 
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apparent phenotype in high driver Dicer KO adrenals at this early time point.  
Finally, phospho-gamma-H2A.X staining was present in high driver Dicer KO 
adrenals, indicating the presence of double stranded DNA damage (Figure 3.5).
 In summary, high driver Dicer KO adrenals showed evidence of increased 
cell cycle arrest and apoptosis in the cortex, consistent with the induction of a 
DNA damage checkpoint and the aplastic cortical phenotype observed at E18.5.
High Driver Dicer KO Adrenals Demonstrate a Unique mRNA Expression 
Profile
 Sf1-Crehigh/Dicerlox/lox high driver Dicer KO mice demonstrated marked 
aplasia of the adrenal cortex that began with increased cellular death at E14.5 
and continued at a rapidly accelerating tempo until E18.5, at which time high 
driver Dicer KO adrenals had undergone nearly complete cortical failure.  
Whether this adrenal failure reflected dysregulation of miRNA biogenesis, or a 
cellular toxicity effect resulting from the accumulation of unprocessed pre-miRs is 
unclear.  Further analysis on the high driver Dicer KO phenotype was therefore 
performed by assessing gene transcript expression in both control and KO 
adrenals over a 2 day time course just prior to the rapid cortical failure seen at 
E18.5.
 E15.5 and E16.5 adrenals from control and high driver Dicer KO embryos 
were harvested and processed as described in Materials and Methods.  Figure 
3.6A shows a heatmap illustrating the differentially expressed gene transcripts in 
high driver Dicer KO adrenals compared with control adrenals at both the E15.5 
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and E16.5 time points.  In E15.5 high driver Dicer KO adrenals, 10 up-regulated 
and 19 down-regulated transcripts were observed that were differentially 
expressed relative to control adrenals.  Similarly, there were less up-regulated 
unique transcripts in E16.5 Dicer KO adrenals than unique down-regulated 
transcripts (19 up vs. 31 down).  The majority of these differentially expressed 
genes overlapped between the E15.5 and E16.5 timepoints in Dicer KO adrenals 
as illustrated in Figure 3.6B.   
 Many of the differentially down-regulated gene transcripts in Dicer KO 
adrenals were related to steroidogenic pathways, with Akr1d1 (a 5-beta 
reductase), and Adh7, (an alcohol dehydrogenase known to be expressed in the 
adrenal cortex), being the two most down-regulated transcripts in Dicer KO 
adrenals common to both E15.5 and E16.5 timepoints.  Additionally, Frzb, a 
secreted Wnt antagonist, was also highly down-regulated in E15.5 and E16.5 
Dicer KO adrenals.  This result was consistent with data from our lab and others, 
which demonstrates a role of the Wnt/β-catenin signaling pathway in adrenal 
development and maintenance, and in the pathology of adrenocortical neoplasia 
[9,38].  
 When we compared all of the differentially up-regulated transcripts in high 
driver Dicer KO adrenals relative to control adrenals at both E15.5 and E16.5, 
numerous genes related to inflammatory or immune processes appeared to be 
over-represented in the data.  We performed a DAVID (Database for Annotation, 
Visualization and Integrated Discovery) analysis which allowed us to identify 
enriched biological themes such as gene ontology (GO) terms and functionally 
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related gene groups.  Comparison across time points and genetic background 
(control vs. Dicer KO) demonstrated that E16.5 high driver Dicer KO adrenals 
were particularly enriched for GO terms related to immune and inflammatory 
response pathway genes (Table 3.1).  These data were consistent with an 
inflammatory process or a cell mediated immune response occurring in high 
driver Dicer KO adrenals that could either contribute to or be a consequence of 
the observed cortical cell death.  
 Interestingly, the most up-regulated transcript in high driver Dicer KO 
adrenals at both E15.5 and E16.5 timepoints was Nr6a1, or germ cell nuclear 
factor (Gcnf).  There was concern this may have been an artifact due to the 
presence of approximately 10kb of the 3’ end of Nr6a1 on the BAC utilized to 
generate the Sf1-Cre transgene.  To further investigate, we performed 
quantitative real-time PCR on E15.5 control and high driver Dicer KO adrenals.  
The up-regulation of Nr6a1 in high driver Dicer KO adrenals was confirmed, as 
we observed at least 2-fold up-regulation of all 3 Nr6a1 isoforms in Dicer KO 
adrenals with isoform 2 being the most robustly up-regulated (Figure 3.7A).  
Additionally, we compared Nr6a1 transcript levels by quantitative real-time PCR 
in the adrenals of wild type animals and animals carrying only the Sf1-Crehigh 
transgene (Figure 3.7B).  We observed a small but significant increase (up to 2 
fold) in isoform 2 of Nr6a1 in adrenals collected from animals harboring only the 
Sf1-Crehigh transgene.  This suggested there may have been transcriptional 
leakage from the transgene, which contains approximately 10kb of the 3’ end of 
the Nr6a1 locus.  Subsequent quantitative real-time PCR analysis performed on 
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cerebral and hepatic tissue isolated from mice bearing only the Sf1-Crehigh 
transgene supported the possibility that the transgene was leaking an incomplete 
3’ transcript of Nr6a1 (Figure 3.7C).  We observed a 2 to 5-fold increase in 
isoform 2 of Nr6a1 in tissues isolated from animals carrying only the Sf1-Crehigh 
transgene.  In comparison, the high driver Dicer KO animals that also carry the 
transgene demonstrated significantly higher levels of this particular isoform (10 to 
16-fold) relative to wild type control animals that were not Dicer KO and did not 
have the Sf1-Crehigh transgene.  Additionally, isoforms 1 and 3 of Nr6a1, which 
were also up-regulated in high driver Dicer KO adrenals, were not significantly 
changed in adrenals taken from animals bearing only the Sf1-Crehigh transgene.  
Taken together, these data confirm that Nr6a1 was up-regulated resulting from 
loss of Dicer in the adrenal cortex.  They also demonstrated transcriptional 
leakage of a partial, 3’ transcript of Nr6a1 from the Sf1-Crehigh transgene alone, 
which accounted for approximately 20-30% of the Nr6a1 up-regulation seen in 
Dicer KO adrenals.  
Down-regulated miRNAs in High Driver Dicer KO Adrenals Are Predicted to 
Target Up-Regulated Gene Transcripts
 In addition to performing Affymetric microarray analysis on high driver 
Dicer KO adrenals, we also profiled and compared miRNA expression for control 
and KO adrenals at E15.5 and E16.5.  As expected, the differentially expressed 
miRNAs in Dicer KO adrenals relative to control were down-regulated to varying 
degrees (Figure 3.8A).  Of these differentially expressed miRNAs, sixteen were 
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common among the E15.5 and E16.5 timepoints analyzed, and several including 
miR-21, have been implicated in the regulation of adrenal physiology [39] (Figure 
3.8B).  Of these down-regulated miRNAs seen at both E15.5 and E16.5, miR 
34c, miR-21, miR-10a, and let-7d were among the most interesting candidates 
for future studies due to the large body of literature available regarding their 
function.    
 We cross-referenced the list of differentially expressed miRNAs with the 
list of differentially expressed gene transcripts in high driver Dicer KO adrenals at 
both E15.5 and E16.5 with the intent of identifying predicted miRNA-target 
mRNA pairs.  Interestingly, the gene transcripts for Nr6a1, Igdcc3, Acvr1c, and 
Greb1l were consistently and repeatedly identified as targets for a small subset 
of miRNAs that were differentially expressed in common among E15.5 and E16.5 
Dicer KO adrenals.  Table 3.2 lists these miRNA-target miRNA pairs and the 
number of predicted sites in each gene target for a given miRNA.  Let-7d, 
miR-10a, miR-202, miR-21, miR-674, and miR-362 were the six miRNAs in 
common between E15.5 and E16.5 Dicer KO adrenals, and it is important to 
reiterate that the four predicted gene targets listed above were also commonly 
up-regulated in Dicer KO adrenals at both time points analyzed.  Finally, we 
compared the predicted binding sites for let-7 in the 3‘ UTRs of both mouse and 
human NR6A1 and ACVR1C.  As illustrated in Table 3.3, the seed sequences 
recognized by let-7 are strongly conserved between human and mouse for all of 
the predicted binding sites that were suggested by the TargetScan algorithm.  In 
addition, these seed sequences were also found to be strongly conserved among 
125
other vertebrate organisms (data not shown).  This phylogenetic conservation of 
predicted let-7 binding sites among various species including between mice and 
humans supports the notion that these binding sites may indeed be functional.  
Similar analyses would need to be performed on the other predicted miRNA-
mRNA interactions described here, and would help determine which predicted 
miRNA-mRNA interactions might be candidates for functional validation studies.    
 In summary, results from the arrays performed on E15.5 and E16.5 control 
versus high driver Dicer KO adrenals showed a unique gene expression profile.  
A number of other transcripts, most notably belonging to the genes Nr6a1, 
Igdcc3, Acvr1c, and Greb1l were also highly up-regulated in Dicer KO adrenal 
glands.  Concurrent miRNA profiling suggested a strong correlation between 
these four differentially expressed genes and several down-regulated miRNA 
species.   There was also data suggestive of an immune/inflammatory response, 
which may have been contributory to the apoptosis and ultimate aplastic 
phenotype observed in Dicer KO adrenal glands.    
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Discussion             
 In this study we generated mice that lacked the enzyme Dicer in the 
adrenal cortex utilizing a Cre-loxP excision system to selectively knock out Dicer 
in cells that expressed the steroidogenic regulator, Sf1.  The first part of the study 
utilized Sf1-Crelow transgenic mice, in which only a small percentage of cortical 
cells underwent Cre mediated excision of the floxed Dicer alleles.  In contrast, 
the Sf1-Crehigh driver resulted in excision of floxed Dicer alleles in all Sf1 
expressing cortical cells, and this mouse was used to determine the 
developmental effects of Dicer loss in the adrenal cortex.
 Dicer ablation has been associated with cellular senescence and 
apoptosis or reduced proliferation in a number of biological models [40-43].  We 
hypothesized that generating Sf1-Crelow Dicer KO mice might result in a 
protracted exhaustion of the adrenal cortex stemming from increased cellular 
turnover of the gland.  Since Dicer knockout mice generated with the Sf1-Crelow 
transgene did not exhibit any significant phenotype even up to 50 weeks of age, 
these data suggested that Dicer loss under the Sf1-Crelow transgene was 
insufficient to produce a measurable effect in our animals, or the adrenals in 
these animals were able to physiologically compensate for the defect, as is seen 
in the contralateral adrenal following unilateral adrenalectomy [44].  In light of 
recent reports that describe heterozygous DICER mutations in humans resulting 
in a familial cancer syndrome, it would be interesting to see what effects, if any, 
may have resulted had Sf1-Crelow Dicer KO animals been followed significantly 
beyond our experimental endpoint of 50 weeks.    
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 We hypothesized that complete Dicer ablation in the developing adrenal 
cortex would result in failure of the tissue.  In contrast to Sf1-Crelow Dicer KO 
animals, Sf1-Crehigh Dicer KO animals exhibited severe adrenal aplasia at E18.5, 
despite normal fetal adrenal formation.  There was a substantial delay between 
Cre-mediated Dicer excision at approximately E10-E11, and the onset of 
phenotypic changes in Dicer KO mice at E14.5-E16.5.  This delay in phenotype 
onset may be due to varying half-lives of Dicer protein and/or mature miRNAs in 
the developing adrenal.  A three to ten day delay has been reported between 
Cre-mediated Dicer excision and depletion of specific miRNAs in the developing 
mouse inner ear, and the possible persistence of other miRNAs has been 
observed long after Dicer ablation in Purkinje cells  [45,46].  Another possibility 
for the delay between Dicer ablation and phenotype onset might be attributed to 
differing sensitivities of various tissues to miRNA mediated gene regulation.  We 
observed increased apoptosis at E14.5 in Dicer KO adrenals, which coincides 
with the time at which the fetal cortex begins to transition to the adult cortex.  It is 
known that the fetal adrenal cortex is eventually replaced by the adult adrenal 
cortex beginning at E14.5 [47].  Our lab has hypothesized that a small sub-
population of fetal adrenocortical cells undergo a change in transcriptional 
programming as they populate the adrenal capsule and become adrenal stem/
progenitor cells responsible for maintaining the adult adrenal cortex [5].  Such a 
transition would be predicted to require significant changes in gene transcription 
and expression, and could make the adrenal cortex more vulnerable to loss of 
miRNA mediated gene regulation in Dicer KO mice at this critical timepoint.
128
 The phenotype observed in the adrenal cortex of Sf1-Crehigh Dicer KO 
animals was caused in part by increased cell cycle arrest and apoptosis, 
resulting in the rapid perinatal death of affected offspring, and was consistent 
with adrenal failure [7].  As cited earlier, many of the previous tissue-specific 
Dicer loss of function studies report both an increase in apoptosis, and in some 
cases proliferative defects.  Additionally, it is known that Dicer ablation in primary 
cell cultures results in the induction of a DNA damage checkpoint, and 
subsequent p19Arf-p53 signaling, leading to increased cellular senescence [40].  
The increased phospho-gamma-H2A.X staining (a marker for double stranded 
DNA damage) we observed in Sf1-Crehigh Dicer KO adrenals is consistent with 
this report.  Adrenals from Sf1-Crehigh Dicer KO embryos also demonstrated a 
significant up-regulation of p21, a cell cycle inhibitor that in part mediates 
senescence, and cleaved Caspase-3, an apoptotic effector caspase.  
The body of data generated by the numerous Dicer loss-of-function models show 
that despite tissue specific differences in observed phenotypes, there may be a 
common mechanistic element across Dicer knockout models.  However, the 
exact mechanism responsible for the observed phenotypes is unknown, and 
several potential actions other than loss of miRNA mediated gene regulation 
could also be involved.
 One possibility may be related to the accumulation of precursor miRNAs 
(pre-miRNAs) that result without the downstream processing provided by Dicer 
[26].  There is evidence for toxic effects associated with oversaturating the 
endogenous miRNA machinery [48].  Animals injected with shRNA vectors into 
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the liver exhibit toxic effects in addition to a decrease in the expression of several 
liver-specific miRNAs, [49] which appears to be a result of oversaturating the 
endogenous miRNA processing machinery.  It is unknown what effect the 
analogous overabundance of immature miRNA species may have on cellular 
homeostasis.
 Dicer is also reported to exhibit miRNA-independent cell survival 
functions, which may also be a contributing factor to consider in the context of 
Dicer loss of function phenotypes.  A recent report by Kaneko et. al. 
demonstrates the necessity of Dicer in clearing Alu and Alu-like B1/B2 RNAs in 
the retinal pigmented epithelium (RPE) of humans and mice, respectively; loss of 
Dicer in these cells resulted in degeneration of the RPE and was not dependent 
on dysfunctional miRNA biogenesis [50].  Similarly, Dicer has been implicated in 
the silencing of centromeric chromatin and regulation of differentiation in mouse 
embryonic stem cells through a non-miRNA-dependent mechanism [26].  These 
reports support the possibility that not all Dicer loss-of-function model 
phenotypes may be necessarily due to impaired miRNA biogenesis, but could 
also be due to defects in other Dicer dependent pathways such as RNAi.  There 
may also be other uncharacterized functions of Dicer that are unrelated to the 
RNAi or miRNA pathways.
 Finally, Dicer in nematodes is reported to undergo specific cleavage at the 
C-terminus of the first RNase III domain in the presence of caspases, generating 
a truncated protein that has DNase activity [51] and produces 3‘ hydroxyl breaks 
in chromosomal DNA, leading to apoptosis.  If a similar phenomenon also occurs 
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in mammals, it could provide a feed-foward loop in which upstream caspase 
activation promotes cell death by acting upon residual Dicer protein that may be 
undetectable in Dicer KO cells.  Regardless of the mode of cell death that is 
induced by Dicer ablation, attempting to determine the specific effects and 
mechanism of Dicer ablation in the context of adrenal development is a 
complicated proposition, and is beyond the scope of this study.
 The second half of this study profiled mRNA and miRNA expression in 
Sf1-Crehigh Dicer KO adrenals at E15.5 and E16.5 with the goal of identifying 
differentially expressed genes resulting from Dicer ablation in knockout adrenals 
prior to failure of the cortex.  In addition, we aimed to identify inversely expressed 
miRNAs that could be potential regulators of down-regulated genes observed in 
Dicer KO adrenals.  Results from the mRNA microarray showed significant down-
regulation of numerous steroidogenic genes, in addition to the sonic hedgehog 
(Shh) transcript.  The latter is intriguing as Shh signaling between subcapsular 
cortical cells and the adrenal capsule is believed to be closely involved in the 
maintenance of an adrenocortical progenitor cell population in the capsule 
[11,52,53].  At E16.5, there were substantially more differentially expressed gene 
transcripts in Dicer KO adrenals, suggesting a progressive disruption of gene 
expression resulting from Dicer ablation.  Additionally, a surprising number of up-
regulated transcripts at both E15.5 and E16.5 were associated with immune or 
inflammatory response processes.  We performed a DAVID analysis on the array 
data, and in E16.5 KOs, there was a significant enrichment of GOTERMS among 
differentially expressed gene transcripts that supported this finding.  However, 
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our histologic analysis of Dicer KO adrenals did not show signs of an active 
inflammatory process.  Further study is needed to determine whether these gene 
changes are related to the phenotype seen in Dicer KO adrenals, or if they are 
indicative of some other processes resulting from Dicer ablation.
 The most interesting result was the up-regulation of Nr6a1 (Gcnf) and 
Acvr1c (Alk7) in Dicer KO adrenals.  These observations were of particular 
interest to us as they are implicated in developmental processes in other tissues 
and organs; they are also shown to be expressed in the developing adrenal 
gland at E14.5 by in situ hybridization [54], although their function in the 
embryonic adrenal is not known.  Nr6a1 is reported to play important functions in 
germ cell and neuronal development [55], and is a paralog of Sf1, residing a 
mere 13kb downstream of Sf1 on chromosome 2 [56].  Despite the close 
proximity to Sf1, the expression pattern of Nr6a1 is relatively distinct, and an 
insulator defining a transcriptional boundary between Sf1 and Nr6a1 has been 
previously described [57].  Nr6a1 is transiently up-regulated following retinoic 
acid induced differentiation of embryonic stem cells [58], and is a potent 
transcriptional repressor of the stem cell pluripotency factor Oct4 [59].  It is also 
required for proper neural stem cell and germ cell development and 
differentiation [55].  The expression and function of Nr6a1 in the adrenal cortex is 
not well characterized, but it could be hypothesized to regulate the differentiation 
of adrenocortical cells from the population of progenitor cells thought to reside in 
the subcapsular region of the cortex.  Further analysis would be required to 
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localize Nr6a1 expression in the normal embryonic adrenal, and to further 
characterize its function, if any, in adrenal development.  
 Acvr1c (Alk7) is a member of the TGF-beta receptor superfamily, and is a 
type I activin receptor, working in conjunction with type II activin receptors to 
transduce signaling of ligands through Smad proteins.  Alk7 has a restricted 
expression pattern in contrast with the activin type IB receptor (Alk4), and is the 
preferred receptor for activin AB, activin B, and Nodal [60,61].  Nodal is a 
secreted ligand belonging to the TGF-beta superfamily, and is responsible for 
mesendoderm formation, node formation, and left-right patterning in the mouse 
[62,63].  It is also able to induce caspase-3 dependent apoptosis by activating 
Alk7 signaling in a variety of cell types, in addition to normal physiologic 
processes such as follicular atresia in the ovary and in trophoblast cells during 
placentation [64-68].  There are no published reports of Alk7 expression or 
function in the adrenal cortex, although its role in the ovary, an organ with a 
common development origin with the adrenal cortex, has been described [69].  It 
is possible that the caspase-3 mediated apoptosis seen in our Sf1-Crehigh Dicer 
KO adrenals may be mediated in part by the up-regulation of Alk7, and would be 
an interesting avenue for further study.  Finally, there is evidence of activin/inhibin 
signaling as a regulator of adrenal-gonadal fate.  It has been shown previously by 
our lab that inhibin KO mice develop gonadal sex-cord tumors, and when 
gonadectomized, adrenocortical tumors.  These adrenocortical tumors display a 
change in cellular identity from adrenal to ovary, which is facilitated by a switch in 
the expression of the transcription factor Gata6 to Gata4.  These transcription 
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factors define the normal adrenal and ovary, respectively [70].  While intriguing, it 
is unknown whether Alk7, although it functions as a receptor for certain activin 
family ligands, has a direct role in this previously observed phenomenon. 
 Interestingly, the literature provides circumstantial evidence of cross-talk 
between the Nr6a1, Alk7, and Wnt/B-catenin pathways.  It is known that Nr6a1 
represses the expression of Cripto1, an epidermal growth factor-Cripto1/FRL1/
cryptic (EGF-CFC) family growth factor that is capable of significantly enhancing 
Nodal mediated signaling through Alk7 [71].  In contrast, Cripto1 is a target of the 
canonical Wnt/β-catenin signaling pathway, and is activated by Lef/Tcf 
transcription factors [72].  Previous studies from our lab demonstrate that active 
β-catenin is present in the subcapsular cortical cells of the adrenal gland as early 
as E14.5, and these cells are believed to receive Wnt signals from the adrenal 
capsule [2].  Further study would be required to confirm the expression and 
potential interaction of these signaling pathways in the normal developing 
adrenal.  If there proves to be some degree of interaction between these 3 
signaling pathways, it would likely require a complex regulatory network to 
maintain homeostasis.  In this regard, miRNAs would be a viable candidate for 
fine-tuning the relative expression levels of each gene, and perturbation of the 
miRNA biogenesis machinery could upset the fine balance required for normal 
adrenal development and homeostasis.
 The miRNAs found to be significantly down-regulated in E15.5 and E16.5 
Dicer KO adrenals provided several interesting avenues for further study.  miR 
34c, miR-21, miR-10a, and let-7d have all been significantly studied in the 
134
literature, particular in aberrant physiological processes such as tumorigenesis.  
Let-7 is the second miRNA to be described after lin-4, and was discovered to 
regulate developmental timing in nematodes [73].  In addition, it is known to 
regulate the oncogenes RAS [74], HMGA2 [75], and MYC [76], and can regulate 
proliferation pathways in human cells [77].  The miR-34 cluster of miRNAs can 
act as a tumor suppressor downstream of p53, and promote cell cycle arrest, 
apoptosis, and senescence [78,79].  In contrast, evidence supports the role of 
miR-10a in retinoic acid induced differentiation of neuroblastoma cells [80], and 
the regulation of Bcl-6, a gene involved in the development of diffuse large B-cell 
lymphoma [81].  miR-21 is implicated in the regulation of aldosterone synthesis in 
the H295 human ACC cell line [39], and believed to promote tumor metastasis 
and tumorigenesis by targeting PTEN [82].  Although these miRNAs have been 
heavily studied in the context of cancer, the body of literature concerning them 
could be useful in elucidating their function in developmental processes, as the 
pathways responsible for organism development and the pathology of cancer 
often coincide.     
! We also compared differentially expressed miRNAs from E15.5 and E16.5 
Dicer KO adrenals with differentially expressed mRNA transcripts using predictive 
algorithms in the TargetScan method in an attempt to identify miRNA-mRNA 
target pairs [83].  We found that Nr6a1 and Acvr1c were both overrepresented as 
predicted targets of a subset of significantly down-regulated miRNAs in both 
E15.5 and E16.5 Dicer KO adrenals, which consisted of the following miRNAs: 
let-7d, miR-10a, miR-202, miR-21, miR-674, and miR-362.  These associations 
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were not likely due to random probability, and therefore suggest that following the 
loss of Dicer function, dysregulation of specific miRNAs may result in de-
repression of Nr6a1 and Acvr1c.  There is considerable literature on the function 
of let-7d and miR-10a as discussed above.  miR-202 expression has been 
observed in mouse adrenals stimulated with ACTH [84], and in porcine adrenals 
associated with psychosocial stress [85].  However, there are very few reports 
regarding the function of miR-674 and miR-362, which have been reported to be 
altered in Huntington’s Disease models [86], and correlated with certain 
melanoma subtypes [87], respectively.  Similarly, little is also known about 
miR-202, although it has been reported to be expressed in the porcine adrenal 
following psycho-social stress [85], and is up-regulated in the circulating blood of 
early stage breast cancer patients [88].  When we compared the predicted let-7 
binding sites in both Nr6a1 and Acvr1c, we found that these sequences were 
highly conserved between mouse, human and other organisms, suggesting these 
sites may be evolutionarily conserved to maintain functional miRNA-mRNA 
interactions.  Further experiments are required to empirically confirm these 
miRNA-target associations, and to establish whether derepression of Nr6a1 and 
Acvr1c by these miRNAs is a result of the Dicer KO phenotype, or is contributory 
to it.    
 This study provided evidence for the requirement of Dicer in the 
developing adrenal cortex.  It further built on the phenotypic observation seen 
here and previously [36] by using a bioinformatic approach to address potential 
underlying mechanisms at the transcriptional level by assessing differentially 
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expressed mRNA and miRNA transcripts in Dicer deficient adrenals.  Although 
we were unable to define specific mechanistic aspects of Dicer ablation in the 
developing adrenal cortex, adrenal enriched miRNAs and potential target mRNAs 
were uncovered, providing several novel avenues of further study.  Subsequent 
analyses of embryonic adrenal glands in the mouse would be more focused 
based on the data collected herein, allowing for the investigation of more specific 
hypotheses regarding Dicer and miRNA biogenesis in the developing adrenal 
gland.  
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Figure 3.1 Histologic analysis of 50 week old control and Sf1-Crelow/Dicerlox/
lox (low driver) Dicer KO adrenals.  
Hematoxylin and eosin staining, in addition to DAB staining for Sf1 and tyrosine 
hydroxylase, were performed as described in Materials and Methods to visualize 






Figure 3.2.  Functional analysis of Sf1-Crelow/Dicerlox/lox Dicer KO adrenals.  
(A) Adrenals weights of 50 week old control (n=4) and Sf1-Crelow/Dicerlox/lox (n=6) 
adrenals normalized and expressed as a ratio to animal body weight.  Horizontal 
lines indicate mean values, vertical lines indicate standard error.  (B) Serum 
corticosterone following ACTH stimulation in 50 week old control and Sf1-Crelow/
Dicerlox/lox animals.  Blood samples were collected at 0, 15, 30, and 60 minutes 
post-ACTH injection, and corticosterone was measured by RIA.  (C) Quantitative 
real-time PCR in total RNA isolated from 50 week old control and low driver Dicer 
KO adrenals.  Fold changes for each sample were calculated relative to the 
mean dC(T) value of all the samples amplified for each gene.  Open bars 
represent control adrenals, while solid bars represent low driver Dicer KO 
adrenals.  All samples were run in triplicate.
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Serum Corticosterone Levels in 50 
Week Old Control
and Sf1-Crelow Dicer KO Mice














































































































Figure 3.3.  Phenotypic results of Sf1-Crehigh/Dicerlox/lox Dicer KO adrenals.  
(A) Gross photos of E16.5 and E18.5 adrenals from control and high driver Dicer 
KO embryos.  Photos from the E16.5 timepoint were taken at a 2x higher 
magnification than the E18.5 photos.  (B) Hematoxylin/eosin staining of 
embryonic control and high driver Dicer KO adrenals at E14.5, E16.5, and E18.5.  
(C) Co-staining for Sf1 and tyrosine hydroxylase (Th) in control and high driver 
Dicer KO embryonic adrenals at E14.5, E16.5, and E18.5.  Sections were 
counterstained with DAPI (blue) prior to visualization.  Images were merged to 
show co-localization.  Scale bars: 100µm.
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Figure 3.4. Assessment for proliferation and cell cycle arrest/apoptosis in 
Sf1-Crehigh Dicer knockout adrenals.  
(A) Co-staining for Sf1 and PCNA in control and high driver Dicer KO adrenals at 
E14.5, E15.5, and E16.5.  Sections were counterstained with DAPI (blue) prior to 
visualization.  Images were merged to show co-localization.  (B) 
Immunohistochemistry with DAB for p21 (Cdkn1a), a cell cycle inhibitor.  Dicer 
KO adrenals appear to have increased p21 staining compared to control 
adrenals.  Tissues were counterstained with hematoxylin diluted 1:10 in 
deionized water.  (C) Immunohistochemistry with DAB for cleaved Caspase3, an 
apoptotic marker.  Dicer KO adrenals demonstrate significantly higher cleaved 
Caspase3 staining relative to control adrenals.  Tissues were counterstained with 





































Figure 3.5. H2A.X staining in Sf1-Crehigh Dicer KO adrenals.
Immunohistochemistry for gamma-H2A.X in Sf1-Crehigh Dicer KO adrenals at 
E14.5, E16.5, and E18.5.  Scale bars: 100µm.
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Figure 3.6.  Affymetrix gene expression data from control and Sf1-Crehigh 
Dicer KO adrenals at E15.5 and E16.5.  
Heatmaps illustrating differentially expressed genes in Dicer KO adrenals versus 
control adrenals at (A) E15.5 and (B) E16.5.  To narrow down differentially 
expressed genes, probe-sets were filtered by excluding those with a false 
discovery rate (FDR) of ≥ .05, and a log fold change of ≤ 1.5 or ≥ -1.5.  Yellow 
bars indicate an increase over the mean chip intensity, and blue indicates a 
decrease over mean intensity.  (C) Venn diagram illustrating common 
differentially expressed genes in E15.5 (light yellow) and E16.5 (light blue) Dicer 
KO adrenals.  Special thanks to Katherine Gurdziel, MS, for her significant 
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Figure 3.7.  Quantitative real time PCR to confirm Nr6a1 expression in Sf1-
Crehigh Dicer KO adrenals and Sf1-Cre only tissues.
(A) Expression of the 3 Nr6a1 transcript isoforms in 3 individual samples of E15.5 
and E16.5 Sf1-Crehigh Dicer KO adrenals relative to control adrenals.  Isoform 2 
(Nr6a1_2) is the most highly expressed at E15.5 by up to 20 fold; isoform 3 
(Nr6a1_3) is also up-regulated relative to control adrenals but to a much lesser 
degree.  At E16.5 isoform 1 (Nr6a1_1) expression is up-regulated in Dicer KO 
adrenals, in addition to isoforms 2 & 3.  (B) Comparison of Nr6a1 expression in 
adrenals from adult mice expressing only the Sf1-Crehigh transgene (Cre), relative 
to wild type (WT) animals.  Expression of isoform 2 seems to suggest leakage of 
a 3’ transcript from the transgene.  (C) Additional Nr6a1 expression data in adult 
adrenal, brain, and liver from mice expressing only the Sf1-Crehigh transgene.  
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Figure 3.8.  Differentially expressed miRNAs in Sf1-Crehigh Dicer KO 
adrenals. 
OpenArray assays for rodent miRNA chips were utilized for differential miRNA 
analysis as described in Materials and Methods.  (A) Differentially expressed 
miRNAs at both E15.5 and E16.5 in Dicer KO adrenal relative to control adrenals 
were filtered to select only those whose expression was changed significantly 
with a p value of ≤ .05.  Only miRNAs with a fold change of ≥ 1.5 or ≤ -1.5 were 
included.  (B) Venn diagram illustrating commonly down-regulated miRNAs at 
both E15.5 and E16.5 in Dicer KO adrenals.  Special thanks to Katherine 
Gurdziel, MS, for her significant contributions to the analysis and 


























E15.5 & E16.5 Down-regulated miRNAs
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A
Table 3.1. DAVID enrichment analysis illustrating differentially expressed 
genes enriched for specific GOTERMS.  
Enriched GOTERMS in E16.5 Dicer KO adrenals relative to E16.5 control (A).  
Enriched GOTERMS in E16.5 versus E15.5 Dicer KO adrenals (B).  FDR ≤ .05 
and fold changes ≥ 1.5 were used as cut-offs.  Special thanks to Katherine 
Gurdziel, MS, for her significant contributions to the analysis and 
organization of the data depicted.
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Cell surface 4.734848485 2.831265284 8.55E-06
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Table 3.2.  Predicted targets of differentially expressed miRNAs.
Differentially expressed miRNAs in E15.5 and E16.5 Dicer KO adrenals were 
cross referenced with differentially expressed genes for predicted mRNA-miRNA 
interactions based on target predictions algorithms from Targetscan 
(targetscan.org).  Some miRNAs have more than one predicted gene target, and 
some predicted targets have multiple potential miRNA binding sites in the 3’ UTR. 
Special thanks to Katherine Gurdziel, MS, for her significant contributions 



























Predicted let-7 binding sites in the 
Nr6a1 3’ UTR
Predicted let-7 binding sites in the 
Acvr1c 3’ UTR
Table 3.3 Predicted let-7 binding sites in Nr6a1 and Acvr1c 3’ UTRs.
Comparative sequence analysis between mouse and human 3’ UTRs based on 
TargetScan (www.targetscan.org) miRNA-mRNA target prediction algorithms.  
The four predicted let-7 sites in the 3’ UTR of mouse (Mmu) Nr6a1 are shown 
and compared with human (Hsa) NR6A1.  let-7 seed sequences are highlighted 
in red.  Additionally, the single predicted let-7 binding site in both human and 
mouse ACVR1C are also shown, with the seed sequence highlighted in red.  The 
predicted binding sites for both genes are tightly conserved between human and 
mouse, in addition with other vertebrates.
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Summary and Future Directions
Summary
! Dicer is an RNase III enzyme necessary for the maturation of miRNAs, 
which fine tune the expression of target genes by repressing their translation at 
the post-transcriptional level.  Loss of Dicer in various biological models results in 
a down regulation of mature miRNAs, which in turn is predicted to disrupt the 
normal, homeostatic expression levels of countless target genes.  In vitro models 
of Dicer loss have demonstrated increased activity of cell cycle inhibitors leading 
to failure to proliferate, senescence and apoptosis.  In other models involving 
stem cells, the lack of Dicer has led to impaired regulation of pluripotency and 
differentiation.  Furthermore, miRNA independent functions for Dicer have been 
described, adding another level of complexity to Dicer mediated regulatory 
functions in the cell.  In vivo, tissue-specific Dicer loss of function results in 
developmental failure of the targeted tissue or organ system that is consistent 
with in vitro observations.  Although it would appear loss of miRNA biogenesis 
due to Dicer inactivation is the primary reason for the phenotypes seen in Dicer 
knockout models, recent evidence suggests miRNA independent function of 
Dicer may also play a role.  miRNAs are also implicated in human disease, and 
DICER expression is often perturbed in human tumors, and genetic 
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haploinsufficiency of the gene has been implicated in familial tumor syndromes.  
Additionally, many specific miRNAs have been implicated in the tumorigenesis of 
human cancers by their ability to regulate cellular processes such as 
differentiation, proliferation, and apoptosis.  This work addresses the 
developmental effects of Dicer loss in the embryonic adrenal cortex, and the 
correlation between miR-483-3p and IGF2 in adrenocortical carcinoma.  
! Chapter 2 confirms the observation that in a high percentage of sporadic 
human ACC cases, IGF2, an adrenocortical mitogen, is highly up-regulated, 
presumably due to defects at the 11p15.5 locus.  In conjunction with IGF2 up- 
regulation in ACC, the miR-483 locus residing in the 2nd intron of IGF2 was 
concurrently over expressed in human ACCs, and the IGF2 expressing human 
ACC cell line, NCI-H295.  This result suggested that the H295 cell line may serve 
as a useful in vitro model in which to study the effects of IGF2 and miR-483-3p 
function in the tumorigenesis of ACC. We designed and constructed several 
molecular tools in an attempt to perturb miR-483-3p expression in vitro and 
identify putative gene targets in the context of ACC.  First, a miR-483-3p 
expression vector was constructed that was able to express miR-483-3p at 
similar levels seen in the H295 cell line.  We also showed that the mature miRNA 
from this expression vector was able to function as an siRNA towards a 
luciferase reporter designed to respond to miR-483-3p.  We also demonstrated 
that endogenous miR-483-3p in H295 cells had a similar inhibitory effect on the 
luciferase reporter.    We also constructed a miR-483-3p “sponge” designed to be 
stably expressed at high levels and act as a competitive inhibitor for miR-483-3p.  
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Unfortunately the results of this sponge were inconclusive, hampered in part by 
the lack of validated miR-483-3p targets that could be used as a gold standard to 
determine the efficacy of the sponge.  Cellular growth of H295A and H295R cells 
transduced with the miR-483-3p sponge was slightly affected, as there were 
fewer viable cells at the endpoint of each experiment compared with controls.  
This may have indicated that the sponge needed further optimization to be more 
efficacious, or that miR-483-3p does not affect cellular proliferation as we had 
hypothesized.  We also determined that nine predicted miR-483-3p target genes 
are significantly down-regulated in primary human ACCs that express high levels 
of endogenous IGF2.  Of these predicted targets, IGF1 and EGR1 were of 
particular interest as IGF1 can act as an adrenal mitogen, and EGR1 is 
described as a tumor suppressor.  We assessed mRNA levels of IGF1 and EGR1 
in H295 cells transduced with the miR-483-3p sponge, and observed a modest 
increase in EGR1 transcript levels, but inconclusive changes in IGF1 transcript 
levels.  These two predicted targets would be ideal candidates for further target 
validation and additional study in the context of ACC.  The molecular tools 
described in Chapter 2 showed promise, but it became readily apparent that with 
the emergence of commercial reagents designed for miRNA research, 
construction of such tools for routine studies would be relatively inefficient from a 
financial and labor perspective.  Furthermore, independent research groups were 
were able to describe potential mechanistic functions of miR-483-3p by reporting 
a putative target, BBC3/PUMA.  This miRNA-target association is consistent with 
the aggressive nature of ACC, as PUMA functions as a pro-apoptotic regulator.  It 
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also supports the theory that miR-483-3p co-expression with IGF2 may synergize 
to drive a more aggressive form of ACC compared to those that do not express 
high levels of IGF2. 
! Chapter 3 describes the results of generating a tissue specific Dicer KO 
mouse.  We utilized both the Sf1-Crelow and Sf1-Crehigh transgenic mice to 
compare the effects of a continual, stochastic model of Dicer inactivation that 
persisted through adulthood (Sf1-Crelow), and a complete model of Dicer 
inactivation in the adrenal cortex that occurred in early development (Sf1-Crehigh).  
Use of the Sf1-Crelow transgene to knock out Dicer in a subset of adrenocortical 
cells did not result in an appreciable phenotype over the course of 50 weeks.  
This suggested that the adrenal cortex was able to compensate for any 
deleterious effects resulting from a continuous, stochastic pattern of Dicer 
inactivation.  Another possible explanation is that Dicer and miRNA biogenesis is 
not as important for the maintenance of the adrenal cortex versus adrenocortical 
development.  In contrast, Sf1-Crehigh Dicer KO mice underwent a dramatic 
failure of the adrenal cortex that began as early as E14.5 and rapidly progressed 
over the subsequent 4 days.  The adrenals in Sf1-Crehigh Dicer KO mice initiated 
normal development, as the presence of adrenal medullary cells implied that 
coalescence of the fetal cortex had occurred.  However, our results show that at 
approximately E14.5, the cortex began to fail, and resulted in the complete loss 
of cortical cells.  Unsurprisingly, these animals died shortly after birth as a result 
of apparent adrenal failure.  Analysis of embryonic Sf1-Crehigh Dicer KO mice 
revealed increased DNA damage, as evidenced by an increase in H2A.X 
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staining, and the up regulation of the cell cycle arrest and apoptotic markers, p21 
and cleaved Caspase-3, respectively.  In contrast, Sf1-PCNA co-
immunofluorescence indicated that proliferation remained unchanged.  Together, 
these result indicate that the E14.5 time point may be host to an important 
developmental milestone that is sensitive to Dicer expression or miRNA 
biogenesis.  As previously cited in Chapter 3, E14.5 has been shown to be the 
developmental time point at which the fetal cortex begins to regress, and Sf1 
expression through the fetal adrenal enhancer is abrogated.  It is possible that 
this critical transition point from fetal to adult cortex is particularly sensitive to 
perturbations in miRNA biogenesis.  Alternatively, if the source of adrenal stem/
progenitor cells indeed comes from Sf1 expressing fetal cortical cells as 
hypothesized, then the inactivation of Dicer in these cells may prevent them from 
completing this transition, resulting in the loss of the adrenal stem/progenitor cell 
pool.  This is an interesting possibility as it has been demonstrated that Dicer 
inactivation can adversely affect stem cells by resulting in the down regulation of 
Oct4.  Additional studies are required to further pursue this hypothesis.
! The second goal of this in vivo project involved profiling the differentially 
expressed mRNA and miRNA transcripts in Sf1-Crehigh Dicer KO adrenals versus 
control adrenals.  We profiled four biological replicates each for Dicer KO and 
control adrenals, then compared differentially expressed mRNA and miRNA 
transcripts between the two experimental groups.  Unsurprisingly, numerous 
steroidogenic enzymes were down regulated in Dicer KO adrenals.  We also 
observed and confirmed through DAVID analysis that a significant number of 
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genes associated with an inflammatory or immune response were up regulated 
as well.  The up-regulation of these immune and inflammatory pathway genes 
could play a role in the phenotype seen in Dicer KO adrenals, which was 
characterized by the expression of cell cycle arrest and apoptotic protein 
markers.  The most intriguing results, however, were the observation that Nr6a1 
and Acvr1c were highly up-regulated in Sf1-Crehigh Dicer KO adrenals.  These 
genes have not been functionally described in the adrenal cortex previously, but 
have been shown to be important in regulating development and differentiation in 
other organ systems.  For example, Nr6a1 regulates the pluripotency and 
differentiation of stem cells by repressing the pluripotency marker Oct4, and has 
also been implicated in the differentiation of neural progenitor cells and the 
regulation of germ cells.  Acvr1c is a type I activin receptor that transduces 
signals from the Nodal ligand, which helps regulate developmental patterning in 
the mouse.  The potential roles of these two genes in adrenal development are 
promising avenues for subsequent study.  We also profiled the differentially 
expressed miRNAs in Dicer KO adrenals compared to controls.  As expected, 
nearly all of the differentially expressed miRNAs in Dicer KO adrenals were down 
regulated, presumably due to the loss of Dicer activity.  There was significant 
overlap in down regulated miRNAs between E15.5 and E16.5 Dicer KO adrenals, 
with 16 commonly down regulated miRNAs.  Of these, miR-34c, miR-21, 
miR-10a, and let-7d were among the most interesting candidates for follow up 
study given the considerable amount of literature that exists regarding their 
function.  As discussed previously in this work, let-7 is known to regulate the 
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oncogenes RAS, HMGA2, and MYC, and can regulate proliferation pathways in 
human cells.  Similarly, the miR-34 cluster of miRNAs can act as a tumor 
suppressors downstream of p53, and promote cell cycle arrest, apoptosis, and 
senescence.  In contrast, evidence supports the role of miR-10a and miR-21 as 
oncogenic miRNAs, as they are often up regulated in human cancers, and in the 
case miR-21, is believed to promote tumor metastasis and tumorigenesis by 
targeting PTEN.  Finally, we asked whether the down regulated miRNAs in Dicer 
KO adrenals were predicted to target any up regulated mRNA transcripts.  We 
matched the list of up regulated mRNA transcripts from E15.5 and E16.5 Dicer 
KO adrenals with down regulated miRNA transcripts using the TargetScan 
algorithm to determine predicted miRNA-target associations.  We discovered that 
a small subset of down regulated miRNAs in Sf1-Crehigh Dicer KO adrenals were 
consistently predicted to target Nr6a1 and Acvr1c.  These miRNAs were as 
follows: let-7d, miR-10a, miR-202, miR-21, miR-674, and miR-362.  Whether the 
up regulation of these two genes is a direct result of or in response to Dicer loss 
is still unknown, and further study is required to validate the predicted miRNA-
mRNA interactions.  These data demonstrate that Dicer loss in the developing 
adrenal cortex resulted in a unique transcriptional and miRNA profile which may 
reflect the underlying mechanism of adrenocortical failure seen in Sf1-Crehigh 
Dicer KO mice.  
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Future Directions
! The results from Chapter 2 confirmed the expression of IGF2 and 
miR-483-3p in ACC, and provided possible gene targets of miR-483-3p for 
subsequent study.  Identifying the gene targets of miR-483-3p would be a 
significant advancement in understanding how this miRNA affects the process of 
tumorigenesis in ACC.  As discussed previously, IGF1 and IGF2 are both 
expressed in the normal adult human adrenal, whereas IGF2 is predominantly 
expressed in the embryonic and cancerous adrenal gland.  Could there be a 
regulatory mechanism by which IGF2 expression indirectly (through miR-483-3p) 
inhibits IGF1?  What are the consequences of IGF1 down regulation, if any, in 
the context of ACC?  Furthermore, the fact that EGR1 is also a predicted 
miR-483-3p target is of great interest considering the role of EGR1 as a tumor 
suppressor gene that is often down regulated in a number of human cancers.  It 
is therefore a reasonable hypothesis that low EGR1 expression seen in primary 
human ACCs is a contributory factor in ACC.   Validation of IGF1 and EGR1 as 
targets of miR-483-3p could be performed using the now widely available 
molecular tools to perturb endogenous miR-483-3p and the H295 cell line could 
be utilized as a model system in which to pursue this goal.  Knockdown of 
miR-483-3p could be accomplished by transfecting synthetic oligos designed to 
competitively inhibit miR-483-3p, and the resulting changes in IGF1 and EGR1 
transcript levels can be measured using standard methods such as quantitative 
real-time PCR.  Protein could also be measured using Western blot techniques.  
In contrast, the effects of miR-483-3p over expression on IGF1 and EGR1 could 
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be studied in the SW13 cell line, which does not express high levels of 
endogenous IGF2 or miR-483-3p.  Over expression of miR-483-3p in such a 
system would be predicted to have an opposite effect on IGF1 and EGR1 
transcript levels.  Finally, target validation would have to be confirmed using an 
exogenous GFP or luciferase reporter construct bearing the 3’ UTR of either 
IGF1 or EGR1.  If the predicted target sequences in the UTRs of both genes are 
responsive to miR-483-3p and responsible for target inhibition, we would expect 
to see decreased reporter activity relative to control reporter constructs in which 
the predicted target sequences are mutated such that they no longer recognize 
miR-483-3p.  The results of these experiments would complement what is known 
about the previously validated miR-483-3p target, BBC3/PUMA.     
! Although BBC3/PUMA has been reported to be a target of miR-483-3p in 
human ACCs, the fact that miRNAs can bind to multiple target mRNAs implies 
there should be other target genes for miR-483-3p that have yet to be identified.  
Identification of additional targets, particularly in the context of ACC, could be 
accomplished using a combination of bioinformatic and molecular techniques to 
empirically determine miRNA-target associations.  Knock down of endogenous 
miRNA could be accomplished using synthetic inhibitory oligos specific for 
miR-483-3p.  Cultured H295 cells subject to miRNA knockdown could then be 
subject to microarray or RNA sequencing analysis to determine the effects of 
miR-483-3p knock down on mRNA expression.  Transcripts shown to be up 
regulated in response to miR-483-3p knock down could then be further 
scrutinized as potential miR-483-3p targets by analyzing the 3’ UTRs for putative 
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binding sites.  Additionally, such an experiment could provide insight into the 
physiologic roles of miR-483-3p.  For example, if miR-483-3p inhibition resulted 
in changes to proliferative, metastatic, or steroidogenic capacity of H295 cells, 
these data could be taken into consideration when filtering down potential 
miR-483-3p targets by placing greater weight on target genes known to regulate 
these physiologic processes.  Then, bioinformatic algorithms such as those 
provided by TargetScan would serve to narrow down the list of targets based on 
putative miR-483-3p binding sites in the 3’ UTR of candidate genes.  The most 
likely candidate genes could be tested in-vitro using molecular tools similar to 
those described in Chapter 2 to confirm miR-483-3p mediated repression of the 
target at both the mRNA and protein level.  
! Evidence suggesting that miR-483-3p can be directly regulated by the 
Wnt/β-catenin signaling pathway has been recently published.  Given that many 
cases of ACC are characterized by inappropriately increased Wnt/β-catenin 
signaling, a logical question to pursue would be whether this signaling pathway 
intersects with the up regulation of IGF2/miR-483-3p that is also seen in many 
ACC cases.  First, the binding of canonical Wnt/β-catenin transcription factors 
such as TCF/LEF to the miR-483-3p locus could be confirmed with chromatin 
immunoprecipitation, and the transcriptional complex defined.  This could be 
performed in the H295 cell line, which harbors an activating mutation in β-
catenin, or heterologous cell lines treated with lithium to activate the Wnt/β-
catenin pathway.  Mutation of the putative TCF/LEF binding sites would help 
confirm these results.  Additionally, the effects of inhibiting Wnt/β-catenin 
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signaling via inhibitors such as cardamonin or the over expression of APC on 
miR-483-3p expression can also be assessed. Finally, published data suggests 
miR-483-3p negatively regulates β-catenin, implying a self regulating feedback 
loop.  While this would initially appear counter intuitive, it is possible that mutated 
β-catenin in the context of ACC is insensitive to miR-483-3p mediated inhibition 
because mutations in the 3’ UTR of β-catenin prevent the binding of miR-483-3p.  
It would be interesting to determine if the β-catenin transcripts in primary human 
ACCs harbor 3’ UTR mutations, rendering itheminsensitive to miR-483-3p 
mediated repression.  Genomic and RNA sequencing of the β-catenin locus 
would help provide insight into this possibility.
! Lastly, further analysis on miRNA expression in ACC could be performed 
by assessing the miRNA profiles of ACCs versus normal or adenomatous 
adrenals.  There are several published studies that pursue this avenue of study, 
but are somewhat limited by small tumor samples sizes.  Nevertheless, these 
reports support the observation made in this thesis that products from the 
miR-483 locus are generally up regulated in ACCs versus adrenal adenomas or 
normal adrenals.  Our laboratory, in collaboration with Dr. Arul Chinnaiyan at the 
University of Michigan, has recently begun a large scale miRNA and mRNA 
profiling study consisting of a significantly larger cohort of primary human ACCs.  
This would allow for a comprehensive study of differentially expressed miRNAs 
and mRNA targets that may be involved in the tumorigenesis of ACC.  Because 
miRNAs can act as both tumor suppressors or oncogenes, highly up-regulated or 
down-regulated miRNAs in ACC may suggest that important target genes are 
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dysregulated as a result.  Large scale bioinformatic analysis to identify predicted 
miRNA-mRNA networks could allow for more detailed classification of ACCs and 
prognostic indicators.  Ultimately, it is hoped that these large scale profiling 
studies will help shed light on the pathophysiology of ACC, and provide clues to 
biochemical or molecular weaknesses in ACC that may be used as targets for 
new and more effect therapies.  
! Chapter 3 discussed the results of Dicer inactivation in the developing 
mouse adrenal cortex, and data from those studies showed that loss of Dicer in 
the embryonic adrenal resulted in the developmental failure of the adrenal cortex. 
This failure became evident as early as E14.5, the time point at which the fetal 
cortex begins to be displaced by the definitive cortex.   Because the Sf1-Cre 
transgene used in these studies is active in both the fetal and definitive cortex, it 
would be of interest to determine whether it is the fetal or definitive cortex that is 
most suscpetible to Dicer inactivation.  This could be accomplished in part by 
generating conditional Dicer KO mice using FAdE-Cre transgenic mice, in which 
the Cre transgene is driven specifically by the FAdE promoter of Sf1.  These mice 
are already available to our lab, and if FAdE-Cre Dicer KO mice recapitulate the 
phenotype seen in Sf1-Cre Dicer KO mice, it would be reasonable to hypothesize 
that Dicer activation might primarily affect the fetal cortex, particularly as the 
adrenal begins to transition from fetal to definitive cortex.  It is hypothesized that 
a small number of fetal adrenocortical cells are destined to become the adrenal 
stem/progenitor cells, which ultimately maintain the definitive adrenal cortex.  If 
this is true, and Dicer loss of function primarily affects fetal cortical cells, it could 
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be speculated that this would negatively affect the specification of adrenal stem/
progenitor cells from fetal cortical cells.  Such a scenario would be consistent 
with the cortical failure seen in Sf1-Crehigh Dicer KO mice in which the adrenal 
cortex fails to maintain itself beyond the E14.5 time point.  To determine the 
specific effects of Dicer inactivation in the definitive cortex would most likely 
require the use of an inducible Cre transgene.  The majority of tissue specific 
Dicer knockout mouse models involves the use of Cre transgenes under the 
control of developmental transcription factors.  This results in Dicer loss of 
function during developmental stages of the organism during which tissues 
undergo significant molecular and physiologic change.  Unfortunately, the Sf1 
definitive adrenal enhancer (DAdE) is still being characterized by our lab, and a 
definitive cortex specific Cre transgene has yet to be developed.  In lieu of this, 
the use of an inducible Sf1-Cre transgene under the control of exogenous 
tamoxifen, for example, might provide a means to study Dicer ablation in the 
definitive cortex.  However, timing the tamoxifen administration and subsequent 
Cre-mediated excision to coincide with the emergence of the definitive cortex 
during embryogenesis would be difficult, and it would be likely that fetal cortical 
cells would also be affected.  However, this system would be a useful tool for 
studying the effects of Dicer inactivation in a fully developed organ in which the 
definitive cortex predominates.  Because many of the existing publications 
detailing tissue specific Dicer inactivation involve developmental models, it is 
difficult to determine if Dicer inactivation is affecting the differentiation and 
specification of developing tissues, or the maintenance of established tissue.  
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Would Dicer ablation in a fully developed, adult adrenal result in complete failure 
of the cortex as was observed in this thesis?  Or would it simply cause increased 
cellular turn over of the adrenal cortex, which could remain in relative 
compensatory homeostasis?  A Dicer KO model under the control of an inducible 
Cre transgene may provide insight into the role of Dicer and miRNA biogenesis in 
the physiology and self renewal of the adult adrenal cortex.  
! In the second aim of Chapter 3, we assessed Dicer KO adrenals at E15.5 
and E16.5 for differentially expressed miRNAs and mRNAs.  The goal was to 
profile transcriptional changes resulting from Dicer inactivation in these adrenal 
glands, identify potential miRNAs involved in adrenal development, and to 
determine any potential miRNA-mRNA associations.  The unexpected 
observation of Nr6a1 and Acvr1c up regulation in Sf1-Crehigh Dicer KO adrenals 
is an avenue for further investigation.  As the expression of these genes has not 
been detailed in the adrenal, it would be important to first confirm mRNA and 
protein expression in both wild type and Sf1-Crehigh Dicer KO embryonic 
adrenals.  Both of these genes are implicated in developmental processes, and 
the ultimate question is whether they have a similar function in the embryonic 
adrenal cortex.  Northern blot analysis from Genepaint (www.genepaint.org) 
demonstrates the presence of Nr6a1 and Acvr1c RNA in the adrenal cortex at 
E14.5.  This is the timepoint at which the adrenal begins to transition from fetal to 
definitive cortex, and therefore, raises the question if Nr6a1 or Acvr1c are 
somehow involved in this process.  Our data shows the loss of Dicer and miRNA 
biogenesis appears to de-repress the expression of these genes, and could be 
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evidence supporting the hypothesis that Nr6a1 and Acvr1c are expressed at 
E14.5 in the developing adrenal, but then must subsequently be down regulated 
for normal development to proceed.  This could be confirmed by assessing the 
expression of these genes over an embryonic time course to elucidate the 
temporal-spatial expression of Nr6a1 and Acvr1c.  Should the expression of 
these genes in the developing adrenals be confirmed, functional studies could be 
initiated by generating adrenal specific mouse knock out models with the Sf1-Cre 
and conditional floxed allele mice.   
! Confirmation of the differentially expressed miRNAs in Sf1-Crehigh Dicer 
KO adrenals would need to be confirmed.  We observed in our results sixteen 
down regulated miRNAs that were common to both the E15.5 and E16.5 time 
points.  Of these, let-7d, miR-10a, miR-21, and miR-34c would be viable 
candidates to initially pursue in subsequent studies due to the large amount of 
literature that is available regarding their function.  The role of these miRNAs in 
adrenal development is an interesting avenue to pursue.  What is the function of 
these miRNAs in the developing adrenal cortex, and is the phenotype in Dicer 
KO adrenals attributable to their down regulation? Confirmation of the expression 
of these miRNAs in the developing adrenal can be accomplished through 
TaqMan based quantitative real time PCR assays, and if necessary, Northern blot 
techniques to localize the spatial expression in the developing adrenal cortex.  
This could aid in the identification of specific miRNAs whose expression is 
required for proper adrenal development.  Additionally, the miRNA arrays we 
performed could also be extended to include the E18.5 time point in wild type 
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adrenals, giving us an additional data point that may aid in elucidating the 
temporal expression of specific miRNAs in the developing adrenal cortex.
! Finally, our data demonstrated that six common miRNAs in both E15.5 
and E16.5 Dicer KO adrenals were consistently predicted to target Nr6a1 and 
Acvr1c, two genes which were highly up regulated in knockout adrenals.  These 
miRNAs were: let-7d, miR-10a, miR-202, miR-21, miR-674, and miR-362.  
TargetScan prediction algorithms demonstrate putative binding to 
phylogenetically conserved sequences in the 3’ UTRs of these genes, but 
empirical evidence of binding and repression would have to gathered.  
Bioinformatic analyses to align and compare the 3’ UTRs of Nr6a1 and Acvr1c 
could be performed initially to identify common sequence motifs that might 
suggest conserved binding sites for these six miRNAs.  Then, using techniques 
and tools discussed in Chapter 2, target validation could be performed in an in 
vitro system in which GFP or luciferase reporter constructs engineered to contain 
the 3’ UTR of putative miRNA targets could be tested against exogenously 
expressed miRNAs of interest.  Lastly, it would be interesting to determine the 
regulatory networks that control the expression of these miRNAs predicted to 
target Nr6a1 and Acvr1c.  Are they co-transcribed with other protein expressing 
genes, or do they respond to transcription factors downstream of canonical 
signaling pathways such as Wnt/β-catenin or Shh which have both been 
implicated in adrenal organogenesis?  Such a question could be investigated by 
taking a bioinformatic approach to determine if there are response elements or 
binding sites in the promoter or regulatory region of these miRNAs that might 
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respond to signaling pathways known to be active in the developing adrenal.  If 
so, in vitro perturbation of the suspected signaling pathway or transcription 
factor(s) should result in a concomitant change in the expression of the miRNA in 
question.  The results from these studies would not only represent a significant 
contribution to the field of adrenal development, but to other areas of 
organogenesis.        
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